Arterial stiffening and vascular calcifications in endâ€s

Nephrology Dialysis Transplantation 15, 1014-1021 DOI: 10.1093/ndt/15.7.1014

Citation Report

#	Article	IF	Citations
2	Renal osteodystrophy: present and future. Clinical and Experimental Nephrology, 2000, 4, 182-186.	0.7	0
3	Renagel®: reducing serum phosphorus in haemodialysis patients. British Journal of Hospital Medicine, 2000, 61, 622-627.	0.3	9
4	Managing phosphate retention: is a change necessary?. Nephrology Dialysis Transplantation, 2000, 15, 1738-1742.	0.4	19
5	Renal osteodystrophy: management of hyperphosphataemia. Nephrology Dialysis Transplantation, 2000, 15, 32-33.	0.4	27
6	Compounds in development to combat hyperphosphataemia. Expert Opinion on Investigational Drugs, 2001, 10, 2185-2190.	1.9	6
8	Imaging of cardiovascular calcifications with electron beam tomography in hemodialysis patients. American Journal of Kidney Diseases, 2001, 37, S62-S65.	2.1	19
9	Vascular calcification in chronic renal failure. Lancet, The, 2001, 358, 1115-1116.	6.3	60
10	Bradykinin in protection against leftventricular hypertrophy. Lancet, The, 2001, 358, 1116-1118.	6.3	18
11	Mecanismos de desarrollo del daño vascular en pacientes en diálisis. Hipertension Y Riesgo Vascular, 2001, 18, 374-382.	0.3	0
12	Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease. Hypertension, 2001, 38, 938-942.	1.3	1,284
13	Undertreatment of Cardiac Risk Factors in Adolescents with Renal Failure. Peritoneal Dialysis International, 2001, 21, 285-289.	1.1	7
14	Vascular Disease and Atherosclerosis in Uremia. Blood Purification, 2001, 19, 139-142.	0.9	9
15	Non-invasive assessments of cardiovascular disease in patients with renal failure. Current Opinion in Nephrology and Hypertension, 2001, 10, 365-369.	1.0	18
16	The place of calcium and calcimimetics in the treatment of secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2001, 16, 15-17.	0.4	5
17	Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrology Dialysis Transplantation, 2001, 16, 459-468.	0.4	124
18	Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Current Opinion in Nephrology and Hypertension, 2001, 10, 741-747.	1.0	64
19	Risk Factors for Cardiovascular Disease in Children on Maintenance Dialysis. Advances in Chronic Kidney Disease, 2001, 8, 180-190.	2.2	19
20	Vascular Calcification of the Venous Side of an Arterious-Venous Fistula. Journal of Vascular Access, 2001, 2, 32-34.	0.5	6

TATION REDO

#	Article	IF	CITATIONS
22	Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney International, 2001, 60, 472-479.	2.6	225
24	Intravenous versus oral vitamin D therapy in dialysis patients: What is the question?. American Journal of Kidney Diseases, 2001, 38, S41-S44.	2.1	14
25	CaCO3 dose and risk of arterial calcification. Nephrology Dialysis Transplantation, 2001, 16, 1075-1076.	0.4	2
26	Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrology Dialysis Transplantation, 2001, 16, 2041-2047.	0.4	51
27	Stiffness of the Abdominal Aorta in Obese Children. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 405-9.	0.4	24
28	Does calcium kill ESRD patients—the skeptic's perspective. Nephrology Dialysis Transplantation, 2002, 17, 229-232.	0.4	32
29	The Effects of Sevelamer Hydrochloride and Calcium Carbonate on Kidney Calcification in Uremic Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 2299-2308.	3.0	102
30	Arterial structure and function in end-stage renal disease. Nephrology Dialysis Transplantation, 2002, 17, 1713-1724.	0.4	183
31	Advanced Coronary and Carotid Arteriopathy in Young Adults With Childhood-Onset Chronic Renal Failure. Circulation, 2002, 106, 100-105.	1.6	670
33	Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrology Dialysis Transplantation, 2002, 17, 14-17.	0.4	26
34	A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrology Dialysis Transplantation, 2002, 17, 1643-1648.	0.4	38
35	Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrology Dialysis Transplantation, 2002, 17, 16-19.	0.4	34
36	Increased Arterial Stiffness in Young Adults with End-Stage Renal Disease since Childhood. Journal of the American Society of Nephrology: JASN, 2002, 13, 2953-2961.	3.0	93
37	Progression of vascular calcification in uraemic patients: can it be stopped?. Nephrology Dialysis Transplantation, 2002, 17, 1365-1368.	0.4	19
38	Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Current Opinion in Nephrology and Hypertension, 2002, 11, 391-395.	1.0	7
39	Augmentation index as a measure of peripheral vascular disease state. Current Opinion in Cardiology, 2002, 17, 543-551.	0.8	261
40	Carotid plaques, but not common carotid intima–media thickness, are independently associated with aortic stiffness. Journal of Hypertension, 2002, 20, 85-93.	0.3	130
41	Impairment of arterial function in chronic renal disease: prognostic impact and therapeutic approach. Nephrology Dialysis Transplantation, 2002, 17, 13-15.	0.4	100

#	Article	IF	CITATIONS
42	Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clinical Science, 2002, 103, 59-65.	1.8	60
43	Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clinical Science, 2002, 103, 59.	1.8	34
44	Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Advances in Chronic Kidney Disease, 2002, 9, 193-199.	2.2	15
45	Cardiovascular calcification in endâ€stage renal disease. Nephrology Dialysis Transplantation, 2002, 17, 336-339.	0.4	83
46	Advanced Oxidation Protein Products, Parathyroid Hormone and Vascular Calcification in Uremia. Blood Purification, 2002, 20, 494-497.	0.9	23
47	Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Nephrology Dialysis Transplantation, 2002, 17, 20-22.	0.4	48
48	Osteodistrofia renal y hepática. Concepto. Etiopatogenia. Manifestaciones clÃnicas. Manejo terapéutico. Medicine, 2002, 8, 4510-4515.	0.0	0
49	Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrology Dialysis Transplantation, 2002, 17, 723-731.	0.4	162
50	Future role of calcimimetics in end-stage renal disease. Advances in Chronic Kidney Disease, 2002, 9, 200-208.	2.2	12
51	Ultrasonic Tissue Characterization of the Carotid Artery in Chronic Renal Failure Patients. Nephron, 2002, 91, 270-275.	0.9	9
52	Hospitalizations for Valvular Heart Disease in Chronic Dialysis Patients in the United States. Nephron, 2002, 92, 43-50.	0.9	20
53	Evolving concepts in the management of renal osteodystrophy. Hong Kong Journal of Nephrology, 2002, 4, 22-28.	0.0	1
54	Acute Coronary Syndromes after Renal Transplantation in Patients with End-Stage Renal Disease Resulting from Diabetes. American Journal of Transplantation, 2002, 2, 274-281.	2.6	40
55	Arterial wall properties in patients with renal failure. American Journal of Kidney Diseases, 2002, 39, 1206-1212.	2.1	56
56	Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. American Journal of Kidney Diseases, 2002, 39, 1245-1254.	2.1	68
57	Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney International, 2002, 61, 638-647.	2.6	387
58	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International, 2002, 62, 245-252.	2.6	1,316
59	Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney International, 2002, 62, 1724-1731.	2.6	297

#	Article	IF	Citations
60	Parathyroidectomy in dialysis patients. Kidney International, 2002, 61, S161-S166.	2.6	46
61	Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney International, 2002, 62, S73-S80.	2.6	110
62	Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and Treatment. Seminars in Dialysis, 2002, 15, 172-186.	0.7	258
63	Opinion: How Should Hyperphosphatemia Be Managed in Dialysis Patients?. Seminars in Dialysis, 2002, 15, 315-317.	0.7	18
64	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 317-319.	0.7	0
65	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 319-321.	0.7	0
66	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 321-324.	0.7	3
67	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 324-326.	0.7	1
68	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 327-328.	0.7	0
69	Cell biology of renal osteodystrophy. Pediatric Nephrology, 2002, 17, 777-789.	0.9	16
70	Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients - importance of glycaemic control. Diabetologia, 2002, 45, 1446-1448.	2.9	75
72	Arterial calcification in diabetes. Current Diabetes Reports, 2003, 3, 28-32.	1.7	142
73	Cardiovascular calcifications in pediatric patients receiving maintenance dialysis. Pediatric Nephrology, 2003, 18, 810-813.	0.9	19
74	Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatric Nephrology, 2003, 18, 969-975.	0.9	62
75	Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatric Nephrology, 2003, 18, 1260-1264.	0.9	53
76	Prevalence and progression of peripheral arterial calcifications in patients with ESRD. American Journal of Kidney Diseases, 2003, 41, 140-148.	2.1	39
77	Vascular calcification in dialysis patients: Pathogenesis and consequences. American Journal of Kidney Diseases, 2003, 41, S96-S99.	2.1	73
78	Cardiovascular complications in chronic kidney disease. American Journal of Kidney Diseases, 2003, 41, 11-17.	2.1	304

#	Article	IF	CITATIONS
79	The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. American Journal of Kidney Diseases, 2003, 42, 303-309.	2.1	173
80	Risk factors for aortic atherosclerosis determined by transesophageal echocardiography in patients with CRF. American Journal of Kidney Diseases, 2003, 42, 277-285.	2.1	5
81	Bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases, 2003, 42, 1-201.	2.1	1,067
82	Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney International, 2003, 64, 263-271.	2.6	109
83	Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney International, 2003, 64, 441-450.	2.6	141
84	Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney International, 2003, 64, 1472-1479.	2.6	97
85	Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney International, 2003, 64, 1653-1661.	2.6	131
86	Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney International, 2003, 63, 1003-1011.	2.6	289
87	Morphology of the heart and arteries in renal failure. Kidney International, 2003, 63, S80-S83.	2.6	84
88	Parathyroidectomy: Whom and when?. Kidney International, 2003, 63, S97-S100.	2.6	64
89	Heart valve calcification and calcium x phosphorus product in hemodialysis patients: Analysis of optimum values for its prevention. Kidney International, 2003, 63, S115-S118.	2.6	36
90	Vascular calcification in the uremic patient: A cardiovascular risk?. Kidney International, 2003, 63, S119-S121.	2.6	41
91	An update on vitamin D as related to nephrology practice: 2003. Kidney International, 2003, 64, S125-S130.	2.6	12
92	The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney International, 2003, 64, S131-S136.	2.6	19
93	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Cardiovascular Disease in Chronic Renal Failure: Pathophysiologic Aspects. Seminars in Dialysis, 2003, 16, 85-94.	0.7	248
94	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure. Seminars in Dialysis, 2003, 16, 111-117.	0.7	148
95	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Calcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney Disease. Seminars in Dialysis, 2003, 16, 140-147.	0.7	86
97	Systolic Hypertension in Hemodialysis Patients. Seminars in Dialysis, 2003, 16, 208-213.	0.7	35

#	ARTICLE	IF	CITATIONS
98	A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. , 2003, 13, 267-274.		67
99	Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification. , 2003, 13, 288-294.		3
100	Hyperphosphataemia in Renal Failure. Drugs, 2003, 63, 577-596.	4.9	59
101	Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Circulation, 2003, 108, 2154-2169.	1.6	3,082
102	Vascular Calcification in Chronic Renal Failure. Nephron Clinical Practice, 2003, 93, c124-c130.	2.3	34
103	Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation, 2003, 18, 1731-1740.	0.4	1,554
104	A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment. American Journal of Hypertension, 2003, 16, 103-110.	1.0	77
106	The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 575-583.	3.0	245
107	Echogenic Carotid Plaques Are Associated With Aortic Arterial Stiffness in Subjects With Subclinical Carotid Atherosclerosis. Hypertension, 2003, 41, 519-527.	1.3	110
108	Cardiovascular Calcifications in Uremic Patients: Clinical Impact on Cardiovascular Function. Journal of the American Society of Nephrology: JASN, 2003, 14, S305-S309.	3.0	197
109	Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Hypertension, 2003, 42, 1050-1065.	1.3	959
110	Determinants of Arterial Distensibility in Patients with Renal Failure. Nephron Physiology, 2003, 95, p43-p48.	1.5	8
111	Slowing the Progression of Vascular Calcification in Hemodialysis. Journal of the American Society of Nephrology: JASN, 2003, 14, S310-S314.	3.0	45
112	BMP-7 Is an Efficacious Treatment of Vascular Calcification in a Murine Model of Atherosclerosis and Chronic Renal Failure. Journal of the American Society of Nephrology: JASN, 2003, 14, 1559-1567.	3.0	198
113	Which Parameter Is More Influential on the Development of Arteriosclerosis in Hemodialysis Patients?. Renal Failure, 2003, 25, 1011-1018.	0.8	13
114	In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrology Dialysis Transplantation, 2003, 18, 1770-1776.	0.4	61
115	Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrology Dialysis Transplantation, 2003, 18, 2iii-8.	0.4	41
116	Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results. European Heart Journal Supplements, 2003, 5, E18-E22.	0.0	2

#	Article	IF	CITATIONS
117	Biochemical Effects of High Dialysate Calcium in Hemodialysis Patients with Hyperparathyroidism: A 10 Month Study. ASAIO Journal, 2003, 49, 70-73.	0.9	5
118	Hyperphosphataemia and treatment with sevelamer in haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 47v-49.	0.4	14
119	Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Current Opinion in Nephrology and Hypertension, 2003, 12, 373-379.	1.0	31
120	Musculoskeletal manifestations of chronic renal failure. Current Opinion in Rheumatology, 2003, 15, 48-54.	2.0	65
121	The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients. American Journal of Nephrology, 2003, 23, 307-314.	1.4	98
122	Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product. American Journal of Nephrology, 2003, 23, 369-379.	1.4	115
124	Indicações de paratireoidectomia no hiperparatireoidismo secundário à insuficiência renal crônica. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 644-653.	1.3	12
125	Usefulness of Brachial-Ankle Pulse Wave Velocity Measurement: Correlation with Abdominal Aortic Calcification Hypertension Research, 2003, 26, 163-167.	1.5	87
126	An Association between Aortic Pulse Wave Velocity, Blood Pressure and Chronic Inflammation in ESRD Patients on Peritoneal Dialysis. International Journal of Artificial Organs, 2003, 26, 188-195.	0.7	30
127	Cardiac Calcium Evaluation in Hemodialysis Patients with Multisection Spiral Computed Tomography. International Journal of Artificial Organs, 2004, 27, 759-765.	0.7	10
128	Trends and Dynamics of Changes in Aortic Pulse Wave Velocity over One-year Observation Period in Patients Treated with Peritoneal Dialysis. International Journal of Artificial Organs, 2004, 27, 904-906.	0.7	6
129	Assessment of Coronary Artery Calcification in Hemodialysis Patients Using Multi-Detector Spiral CT Scan. Hypertension Research, 2004, 27, 527-533.	1.5	92
130	Left Ventricular Hypertrophy Is Associated with Arterial Stiffness and Vascular Calcification in Hemodialysis Patients. Hypertension Research, 2004, 27, 47-52.	1.5	147
131	Calcium agonists in hyperparathyroidism. Expert Opinion on Investigational Drugs, 2004, 13, 229-244.	1.9	5
132	Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2208-2218.	3.0	2,350
133	Calcium, Phosphate, and Parathyroid Hormone Levels in Combination and as a Function of Dialysis Duration Predict Mortality: Evidence for the Complexity of the Association between Mineral Metabolism and Outcomes. Journal of the American Society of Nephrology: JASN, 2004, 15, 770-779.	3.0	335
134	Arterial Calcifications and Bone Histomorphometry in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 1943-1951.	3.0	537
135	Vascular Calcification Mechanisms. Journal of the American Society of Nephrology: JASN, 2004, 15, 2959-2964.	3.0	480

#	Article	IF	CITATIONS
136	Successful Treatment of an Adynamic Bone Disorder with Bone Morphogenetic Protein-7 in a Renal Ablation Model. Journal of the American Society of Nephrology: JASN, 2004, 15, 359-369.	3.0	106
137	Safety and Efficacy of Sevelamer in the Treatment of Uncontrolled Hyperphosphataemia of Haemodialysis Patients. Nephron Clinical Practice, 2004, 97, c17-c22.	2.3	19
138	Cardiac Disease in Chronic Kidney Disease: Current Understandings and Opportunities for Change. Blood Purification, 2004, 22, 21-27.	0.9	13
139	Calcimimetics versus Vitamin D: What Are Their Relative Roles?. Blood Purification, 2004, 22, 38-43.	0.9	9
140	Impact of Serum Parathyroid Hormone Concentration and Its Regulatory Factors on Arterial Stiffness in Patients Undergoing Maintenance Hemodialysis. Blood Purification, 2004, 22, 293-297.	0.9	18
141	Rights of chronic renal failure patients undergoing chronic dialysis therapy. Nephrology Dialysis Transplantation, 2004, 19, 30-38.	0.4	11
142	Importance of hyperphosphataemia in the cardio-renal axis. Nephrology Dialysis Transplantation, 2004, 19, i4-i8.	0.4	11
143	Vascular calcification in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, v59-v66.	0.4	166
144	Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 1489-1496.	0.4	258
145	Association of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 2564-2569.	0.4	31
146	Acute effect of haemodialysis on arterial stiffness: membrane bioincompatibility?. Nephrology Dialysis Transplantation, 2004, 19, 2797-2802.	0.4	17
147	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney International, 2004, 65, 1790-1794.	2.6	149
148	Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney International, 2004, 65, 1914-1926.	2.6	185
149	Atherosclerosis and uremic retention solutes. Kidney International, 2004, 66, 1719-1731.	2.6	34
150	Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: The Framingham Heart Study. Kidney International, 2004, 66, 2017-2021.	2.6	78
151	Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney International, 2004, 66, 2022-2031.	2.6	93
152	Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro11See Editorial by Towler, p. 2467 Kidney International, 2004, 66, 2293-2299.	2.6	291
153	The Consequences of Uncontrolled Secondary Hyperparathyroidism and Its Treatment in Chronic Kidney Disease. Seminars in Dialysis, 2004, 17, 209-216.	0.7	84

#	Article	IF	CITATIONS
154	Time and exercise improve phosphate removal in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 85-89.	2.1	110
155	Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 479-484.	2.1	47
156	Vascular calcification in chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 572-579.	2.1	381
157	Effect of dialysis modality on plasma fibrinogen concentration: A meta-analysis. American Journal of Kidney Diseases, 2004, 44, 941-949.	2.1	15
158	The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders. Experimental and Molecular Pathology, 2004, 76, 182-187.	0.9	26
159	The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatric Nephrology, 2004, 19, 478-484.	0.9	36
160	Vascular intramural strain imaging using arterial pressure equalization. Ultrasound in Medicine and Biology, 2004, 30, 761-771.	0.7	68
161	A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 1480-1488.	0.4	266
162	Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification. Endocrine Reviews, 2004, 25, 629-672.	8.9	238
163	Pathophysiology of Vascular Calcification in Chronic Kidney Disease. Circulation Research, 2004, 95, 560-567.	2.0	440
164	Uremic vasculopathy. Seminars in Nephrology, 2004, 24, 413-416.	0.6	15
165	Arterial stiffness and function in end-stage renal disease. Advances in Chronic Kidney Disease, 2004, 11, 202-209.	0.6	70
166	Arterial calcification in chronic kidney disease. Seminars in Nephrology, 2004, 24, 403-407.	0.6	16
167	Mechanisms of vascular calcification in uremia. Seminars in Nephrology, 2004, 24, 401-402.	0.6	38
168	Vascular calcification in chronic kidney disease. Seminars in Nephrology, 2004, 24, 61-68.	0.6	48
169	Management of Hyperphosphataemia in Dialysis Patients. Drugs and Aging, 2004, 21, 153-165.	1.3	18
170	Secondary hyperparathyroidism: Review of the disease and its treatment. Clinical Therapeutics, 2004, 26, 1976-1993.	1.1	75
171	Imaging and assessment of vascular calcification in chronic kidney disease patients. Current Opinion in Nephrology and Hypertension, 2004, 13, 637-640.	1.0	4

#	Article	IF	CITATIONS
172	Fetuin-A and extraosseous calcification in uremia. Current Opinion in Nephrology and Hypertension, 2005, 14, 337-342.	1.0	60
173	Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. Journal of Hypertension, 2005, 23, 1067-1075.	0.3	98
174	Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?. Current Opinion in Nephrology and Hypertension, 2005, 14, 355-360.	1.0	20
175	Which vitamin D derivative to prescribe for renal patients. Current Opinion in Nephrology and Hypertension, 2005, 14, 343-349.	1.0	34
176	Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension, 2005, 23, 557-562.	0.3	13
177	Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench. Current Opinion in Nephrology and Hypertension, 2005, 14, 519-524.	1.0	27
178	Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Current Opinion in Nephrology and Hypertension, 2005, 14, 525-531.	1.0	219
179	Phosphate binder therapy for attainment of K/DOQIâ"¢ bone metabolism guidelines. Kidney International, 2005, 68, S7-S14.	2.6	14
180	Reversibility of Calcitriol-Induced Medial Artery Calcification in Rats With Intact Renal Function. Journal of Bone and Mineral Research, 2005, 21, 484-490.	3.1	107
181	Phosphorus Management in End-Stage Renal Disease. Seminars in Dialysis, 2005, 18, 8-12.	0.7	12
182	VITAMIN D IN HEALTH AND DISEASE: The Role of Vitamin D in Vascular Calcification in Chronic Kidney Disease. Seminars in Dialysis, 2005, 18, 307-314.	0.7	50
183	Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney International, 2005, 67, 1532-1538.	2.6	23
184	Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factors. Kidney International, 2005, 67, 1576-1582.	2.6	135
185	Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney International, 2005, 67, 2015-2020.	2.6	73
186	Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney International, 2005, 68, 271-277.	2.6	43
187	Infusion of angiotensin II reduces loss of glomerular capillary area in the early phase of anti-Thy-1.1 nephritis possibly via regulating angiogenesis-associated factors. Kidney International, 2005, 68, 704-722.	2.6	18
188	Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney International, 2005, 68, 1258-1266.	2.6	63
189	Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney International, 2005, 68, 1793-1800.	2.6	499

#	ARTICLE	IF	CITATIONS
190	Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney International, 2005, 68, 2809-2813.	2.6	114
191	Calcification and cardiovascular problems in renal failure. Kidney International, 2005, 67, S120-S127.	2.6	55
192	Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney International, 2005, 67, S13-S20.	2.6	24
193	Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney International, 2005, 67, S43-S50.	2.6	33
194	Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives. Kidney International, 2005, 68, S142-S151.	2.6	18
195	Health and Economic Consequences of Sevelamer Use for Hyperphosphatemia in Patients on Hemodialysis. Value in Health, 2005, 8, 549-561.	0.1	34
196	Arterial structural and functional alterations in uraemia. European Journal of Clinical Investigation, 2005, 35, 85-88.	1.7	18
197	Ultrafiltration improves aortic compliance in haemodialysis patients. Journal of Human Hypertension, 2005, 19, 439-444.	1.0	21
198	Prospective Randomized Multicenter Trial of Sevelamer Hydrochloride and Calcium Carbonate for the Treatment of Hyperphosphatemia in Hemodialysis Patients in Japan. Therapeutic Apheresis and Dialysis, 2005, 9, 340-346.	0.4	40
199	Efficacy of Combined Sevelamer and Calcium Carbonate Therapy for Hyperphosphatemia in Japanese Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2005, 9, 347-351.	0.4	19
200	Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. American Journal of Kidney Diseases, 2005, 45, 494-501.	2.1	297
201	K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. American Journal of Kidney Diseases, 2005, 45, 16-153.	2.1	543
202	Arterial Stiffness in Renal Patients: An Update. American Journal of Kidney Diseases, 2005, 45, 965-977.	2.1	138
203	Comparison of Surgically Removed Cardiac Valves of Patients With ESRD With Those of the General Population. American Journal of Kidney Diseases, 2005, 46, 86-93.	2.1	50
204	Cardiovascular Risk and Renal Transplantation: Post Hoc Analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases, 2005, 46, 529-536.	2.1	119
205	The Hemodynamic Effect of Calcium Ion Concentration in the Infusate During Predilution Hemofiltration in Chronic Renal Failure. American Journal of Kidney Diseases, 2005, 46, 470-480.	2.1	6
206	Coronary Artery Calcification in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 1942-1947.	2.6	59
207	Cinacalcet: A New Treatment for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. Pharmacotherapy, 2005, 25, 709-716.	1.2	12

ARTICLE IF CITATIONS Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its 208 4.7 1 therapeutic value. Core Evidence, 2005, Volume 1-Íssues 1 & 2, 0-0. 209 Cardiovascular Disease in Patients with Chronic Kidney Disease., 2005, , 158-173. Continuous Ambulatory Peritoneal Dialysis Patients Show High Prevalence of Carotid Artery 210 Calcification which is Associated with a Higher Left Ventricular Mass Index. Journal of Korean 7 1.1 Medical Science, 2005, 20, 848. Vascular Calcifications in Chronic Kidney Disease: Are There New Treatments?. Current Vascular Pharmacology, 2005, 3, 181-184. Cardiovascular Calcification Progression – A Comparison of Sevelamer and Calcium-Based Phosphate 212 0.9 1 Binders. Blood Purification, 2005, 23, 20-23. Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, S95-S102. 44 The Fall and Rise of Parathyroidectomy in U.S. Hemodialysis Patients, 1992 to 2002. Journal of the 214 3.0 106 American Society of Nephrology: JASN, 2005, 16, 210-218. Strategies for Improving Long-Term Survival in Patients with ESRD. Journal of the American Society of 57 Nephrology: JASN, 2005, 16, S120-S127. Altered Morphologic Properties of Large Arteries in Children with Chronic Renal Failure and after 216 3.0 246 Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1494-1500. Evolution and modulation of age-related medial elastocalcinosis: Impact on large artery stiffness and 1.8 isolated systolic hypertension. Cardiovascular Research, 2005, 66, 307-317. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis 218 523 0.4 Transplantation, 2005, 20, 1048-1056. Sevelamer hydrochloride: a calcium- and metal-free phosphate binder. Therapy: Open Access in Clinical Medicine, 2005, 2, 823-834. Renal Advances in Ultrasound Elasticity Imaging: Measuring the Compliance of Arteries and Kidneys in 220 0.9 47 End-Stage Renal Disease. Blood Purification, 2005, 23, 10-17. The prevalence of carotid artery calcification on the panoramic radiographs of patients with renal disease. Dentomaxillofacial Radiology, 2005, 34, 16-19. 1.3 Hyperphosphatemia and phosphate binders. American Journal of Health-System Pharmacy, 2005, 62, 222 0.5 30 2355-2361. THE USE OF TELEMEDICINE TO ASSESS AND ADVISE PATIENTS REGARDING DIETARY TREATMENT OF HYPERPHOSPHATAEMIA. Journal of Renal Care, 2005, 31, 215-218. Regulation of Vascular Calcification. Circulation Research, 2005, 96, 717-722. 270 224 2.0 Uremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E Knockout 179 Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 109-116.

#	Article	IF	CITATIONS
226	Myocardial Stiffness, Cardiac Remodeling, and Diastolic Dysfunction in Calcification-Prone Fetuin-A–Deficient Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 3357-3364.	3.0	119
227	Cardiac and Vascular Adaptation in Pediatric Patients with Chronic Kidney Disease: Role of Calcium-Phosphorus Metabolism. Journal of the American Society of Nephrology: JASN, 2005, 16, 2796-2803.	3.0	170
228	Accumulation of Metals and Minerals from Phosphate Binders. Blood Purification, 2005, 23, 2-11.	0.9	19
229	Arterial Compliance in Elderly Men with Chronic Kidney Disease. American Journal of Nephrology, 2005, 25, 451-458.	1.4	4
230	Calcaneal Osteopenia Is a New Marker for Arterial Stiffness in Chronic Hemodialysis Patients. American Journal of Nephrology, 2005, 25, 196-202.	1.4	19
231	Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2005, 20, 404-412.	0.4	39
232	Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2005, 20, 760-767.	0.4	53
233	Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrology Dialysis Transplantation, 2005, 20, 424-430.	0.4	31
234	1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar®/Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2005, 20, 1370-1377.	0.4	129
235	Is 2.5 mEq/L the Optimal Calcium Concentration of Dialysate in the Use of Sevelamer Hydrochloride? A Study of the Dialysate Calcium Concentration Recommended by K/DOQI Guidelines. Therapeutic Apheresis and Dialysis, 2005, 9, 24-31.	0.4	12
236	Combination Therapy with Sevelamer Hydrochloride and Calcium Carbonate in Japanese Patients with Long-Term Hemodialysis: Alternative Approach for Optimal Mineral Management. Therapeutic Apheresis and Dialysis, 2005, 9, 11-15.	0.4	30
237	Cardiovascular Calcification in Patients With End-stage Renal Disease. Therapeutic Apheresis and Dialysis, 2005, 9, 208-210.	0.4	20
238	Dialysis dose as a determinant of adequacy. Seminars in Nephrology, 2005, 25, 76-80.	0.6	8
239	Traditional and Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease. Medical Clinics of North America, 2005, 89, 587-611.	1.1	51
240	Inflammation and Vascular Calcification. Blood Purification, 2005, 23, 64-71.	0.9	102
241	Cardiac Valve Calcifications and Left Ventricular Hypertrophy in Hemodialysis Patients. Renal Failure, 2005, 27, 733-738.	0.8	15
242	Biology of Vascular Calcification in Renal Disease. Nephron Experimental Nephrology, 2005, 101, e134-e138.	2.4	16
243	Calcium Loading, Calcium Accumulation, and Associated Cardiovascular Risks in Dialysis Patients. Blood Purification, 2005, 23, 12-19.	0.9	19

#	Article	IF	CITATIONS
244	Uremic Toxicity. , 2005, , 87-121.		2
245	Failure of aneurysm sac shrinkage after endovascular repair; the effect of mural calcification. Clinical Radiology, 2005, 60, 1290-1294.	0.5	4
246	Vascular Calcification in Dialysis Patients. Transplantation Proceedings, 2005, 37, 4183-4186.	0.3	16
247	Higher Brachial-Ankle Pulse Wave Velocity Is Associated with More Advanced Carotid Atherosclerosis in End-Stage Renal Disease. Hypertension Research, 2005, 28, 9-14.	1.5	77
249	Effects of dietary calcium on atherosclerosis, aortic calcification, and icterus in rabbits fed a supplemental cholesterol diet. Lipids in Health and Disease, 2006, 5, 16.	1.2	30
250	Impact of Convective Flow on Phosphorus Removal in Maintenance Hemodialysis Patients. , 2006, 16, 47-53.		68
251	Serum Fetuin-A Levels Link Inflammation and Cardiovascular Calcification in Hemodialysis Patients. American Journal of Nephrology, 2006, 26, 423-429.	1.4	63
252	Management of Vascular Calcification in CKD Patients. Seminars in Nephrology, 2006, 26, 38-41.	0.6	8
253	Effect of Etidronic Acid on Arterial Calcification in Dialysis Patients. Clinical Drug Investigation, 2006, 26, 215-222.	1.1	61
254	The safety of phosphate binders. Expert Opinion on Drug Safety, 2006, 5, 675-686.	1.0	7
255	Carotid atherosclerosis and arterial peripheral pulse wave velocity in cerebral thrombosis. Journal of Clinical Neuroscience, 2006, 13, 45-49.	0.8	18
257	Vascular Access Outcomes as a Predictor of Development of Chronic Allograft Nephropathy. Transplantation Proceedings, 2006, 38, 2657-2658.	0.3	1
258	Coronary Artery Calcification, Common Carotid Artery Intima-Media Thickness and Aortic Pulse Wave Velocity in Patients on Peritoneal Dialysis. International Journal of Artificial Organs, 2006, 29, 736-744.	0.7	28
259	Predictors of Mortality in End-Stage Renal Disease Patients with Mitral Annulus Calcification. American Journal of the Medical Sciences, 2006, 331, 124-130.	0.4	6
260	Uremic Vascular Calcification. Journal of Investigative Medicine, 2006, 54, 380-384.	0.7	24
262	Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Current Opinion in Nephrology and Hypertension, 2006, 15, 105-110.	1.0	67
263	The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease. Vascular Disease Prevention, 2006, 3, 165-172.	0.2	0
264	Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology, 2006, 11, 142-146.	0.7	9

#	ARTICLE	IF	CITATIONS
265	Heart valve calcifications in patients with end-stage renal disease: Analysis for risk factors. Nephrology, 2006, 11, 494-496.	0.7	34
266	Vascular Calcifications in Uremia: Old Concepts and New Insights. Seminars in Dialysis, 2006, 19, 60-68.	0.7	49
267	The Influences of Method of Calcium Correction and the Timing of Blood Collection on Application of The K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan. Therapeutic Apheresis and Dialysis, 2006, 10, 257-261.	0.4	8
268	Doppler echocardiograph evaluation of pulmonary hypertension in patients undergoing hemodialysis. Hemodialysis International, 2006, 10, 356-359.	0.4	53
269	Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. European Journal of Clinical Investigation, 2006, 36, 51-62.	1.7	114
270	Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney International, 2006, 69, 1424-1430.	2.6	29
271	Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney International, 2006, 70, 351-357.	2.6	306
272	The role of calcimimetics in chronic kidney disease. Kidney International, 2006, 70, S68-S72.	2.6	12
273	Introduction: Improving outcomes in chronic kidney disease. Kidney International, 2006, 70, S1-S4.	2.6	3
274	A new era in phosphate binder therapy: What are the options?. Kidney International, 2006, 70, S10-S15.	2.6	36
275	Management of musculoskeletal complications in endstage renal disease: an update. Clinical Rheumatology, 2006, 25, 440-442.	1.0	2
276	Relationships between pulse wave velocity and heart rate variability in healthy men with a range of moderate-to-vigorous physical activity levels. European Journal of Applied Physiology, 2006, 98, 516-523.	1.2	22
277	Carotid Plaques and Their Predictive Value for Cardiovascular Disease and All-Cause Mortality in Hemodialysis Patients Considering Renal Transplantation: A Decade Follow-Up. American Journal of Kidney Diseases, 2006, 47, 888-897.	2.1	33
278	Increased Pulse Wave Velocity Is Associated With Low Creatinine Clearance and Proteinuria in a Screened Cohort. American Journal of Kidney Diseases, 2006, 47, 790-797.	2.1	61
279	Hyperphosphataemia and related mortality. Nephrology Dialysis Transplantation, 2006, 21, 273-280.	0.4	18
280	Calcifications, Arterial Stiffness and Atherosclerosis. , 2006, 44, 234-244.		117
281	Current treatment options in secondary renal hyperparathyroidism. Nephrology Dialysis Transplantation, 2006, 21, 23-28.	0.4	19
282	Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrology Dialysis Transplantation, 2006, 21, 459-465.	0.4	32

#	Article	IF	CITATIONS
283	ls it practical to screen dialysis patients for vascular calcification?. Nephrology Dialysis Transplantation, 2006, 21, 251-254.	0.4	14
284	Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrology Dialysis Transplantation, 2006, 21, 1293-1299.	0.4	82
285	Measurement of vascular calcification using CT fistulograms. Nephrology Dialysis Transplantation, 2006, 22, 484-490.	0.4	14
286	Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs. Expert Opinion on Pharmacotherapy, 2006, 7, 2215-2224.	0.9	12
287	Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrology Dialysis Transplantation, 2006, 21, 2065-2068.	0.4	25
288	Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified. Nature Clinical Practice Nephrology, 2006, 2, 337-339.	2.0	5
289	Molecular Determinants of Vascular Calcification: A Bench to Bedside View. Current Molecular Medicine, 2006, 6, 515-524.	0.6	35
290	Foot Gangrene in Patients with End-Stage Renal Disease: A Case Control Study. Angiology, 2006, 57, 355-361.	0.8	9
291	Cholesterol, Lipids and Arterial Stiffness. , 2006, 44, 261-277.		69
292	The Case against Calcium-Based Phosphate Binders. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 697-703.	2.2	89
293	Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, 262-270.	3.0	160
294	Impact of Treatment with Calcimimetics on Hyperparathyroidism and Vascular Mineralization. Journal of the American Society of Nephrology: JASN, 2006, 17, S281-S285.	3.0	12
295	Introduction. Journal of the American Society of Nephrology: JASN, 2006, 17, S1-S3.	3.0	243
296	Calcification and Cardiovascular Health. Hypertension, 2006, 47, 1027-1034.	1.3	114
297	Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium × Phosphate. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 305-312.	2.2	64
298	Calcimimetic R-568 Decreases Extraosseous Calcifications in Uremic Rats Treated with Calcitriol. Journal of the American Society of Nephrology: JASN, 2006, 17, 795-804.	3.0	137
299	Leptin and Vascular Smooth Muscle. Current Vascular Pharmacology, 2006, 4, 383-393.	0.8	10
300	MULTIDISCIPLINARY APPROACH FOR PRESCRIPTIVE MANAGEMENT OF MINERAL AND BONE METABOLISM IN CHRONIC KIDNEY DISEASE: DEVELOPMENT OF A DIETETIC LED PROTOCOL. Journal of Renal Care, 2006, 32, 187-191.	0.6	4

#	Article	IF	CITATIONS
301	Aortic Stiffness in Patients Undergoing Hemodialysis is Positively Related to Antigen Presenting Cell-Dependent T-Lymphocyte Reactivity. Renal Failure, 2006, 28, 63-68.	0.8	1
302	Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes. Journal of the American Society of Nephrology: JASN, 2006, 17, S267-S273.	3.0	131
303	What serum calcium can tell us and what it can't. Nephrology Dialysis Transplantation, 2006, 21, 29-32.	0.4	50
304	Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrology Dialysis Transplantation, 2007, 23, 321-327.	0.4	31
305	Pulse wave velocity a useful tool for cardiovascular surveillance in pre-dialysis patients. Nephrology Dialysis Transplantation, 2007, 22, 3527-3532.	0.4	24
306	Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrology Dialysis Transplantation, 2007, 23, 82-90.	0.4	45
307	Gene Polymorphisms and Serum Alpha-2-Heremans-Schmid Levels in Italian Haemodialysis Patients. American Journal of Nephrology, 2007, 27, 639-642.	1.4	20
308	Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney International, 2007, 71, 312-317.	2.6	21
309	Determinants of Arterial Wall Stiffness and Peripheral Artery Occlusive Disease in Nondiabetic Hemodialysis Patients. Hypertension Research, 2007, 30, 377-385.	1.5	32
310	Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney International, 2007, 71, 252-259.	2.6	70
311	Emerging drugs for hyperphosphatemia. Expert Opinion on Emerging Drugs, 2007, 12, 355-365.	1.0	31
312	The fallacy of the calcium-phosphorus product. Kidney International, 2007, 72, 792-796.	2.6	138
313	Control of hyperphosphatemia beyond phosphate. Kidney International, 2007, 71, 376-379.	2.6	12
314	Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients. Hypertension, 2007, 49, 1278-1284.	1.3	73
315	Estimated Glomerular Filtration Rate and Urinary Albumin Excretion Are Independently Associated with Greater Arterial Stiffness: The Hoorn Study. Journal of the American Society of Nephrology: JASN, 2007, 18, 1942-1952.	3.0	182
316	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 766-785.	2.2	30
317	Arterial Stiffness and Osteoporosis in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1259-1265.	2.5	336
318	Pulse Pressure Is an Independent Predictor of Aortic Stiffness in Patients with Mild to Moderate Chronic Kidney Disease. Kidney and Blood Pressure Research, 2007, 30, 283-288.	0.9	11

#	Article	IF	CITATIONS
319	Phosphate Salivary Secretion in Hemodialysis Patients: Implications for the Treatment of Hyperphosphatemia. Nephron Physiology, 2007, 105, p52-p55.	1.5	30
320	Undercarboxylated Matrix GLA Protein Levels Are Decreased in Dialysis Patients and Related to Parameters of Calcium-Phosphate Metabolism and Aortic Augmentation Index. Blood Purification, 2007, 25, 395-401.	0.9	61
321	Evaluation of the role of severe hyperparathyroidism on coronary artery calcification in dialysis patients. Clinical Nephrology, 2007, 67, 89-95.	0.4	17
322	Vitamin D Deficiency and Secondary Hyperparathyroidism Among Patients with Chronic Kidney Disease. American Journal of the Medical Sciences, 2007, 333, 201-207.	0.4	32
323	Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension, 2007, 16, 409-415.	1.0	25
324	Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?. Clinical Science, 2007, 112, 543-555.	1.8	99
325	Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients. Vascular Disease Prevention, 2007, 4, 205-212.	0.2	1
326	Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney International, 2007, 71, 802-807.	2.6	153
328	Early Coronary Calcification in Children and Young Adults With End-Stage Renal Disease. Transplantation Proceedings, 2007, 39, 37-39.	0.3	15
329	Reduction in Arterial Stiffness With Angiotensin II Antagonism and Converting Enzyme InhibitionA Comparative Study Among Malay Hypertensive Subjects With a Known Genetic Profile. American Journal of Hypertension, 2007, 20, 184-189.	1.0	29
330	Arterial structure and function in end-stage renal disease. Artery Research, 2007, 1, 79.	0.3	12
331	Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis, 2007, 192, 131-137.	0.4	101
332	Chronic kidney disease and cardiovascular risk. Journal of the American Society of Hypertension, 2007, 1, 178-184.	2.3	24
334	Study of vascular smooth muscle cell calcification induced by hyperphosphate and intervented by phosphonoformic acid. Journal of Nanjing Medical University, 2007, 21, 377-381.	0.1	1
336	A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Current Medical Research and Opinion, 2007, 23, 3167-3175.	0.9	65
337	Vascular function in patients with end-stage renal disease and/or coronary artery disease: A cardiac magnetic resonance imaging study. Kidney International, 2007, 71, 68-73.	2.6	26
338	Angiotensin II Receptor Antagonists Supplementation is Associated with Arterial Stiffness: Insight from a Retrospective Study in 116 Peritoneal Dialysis Patients. Renal Failure, 2007, 29, 843-848.	0.8	3
339	Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency. Journal of the American Society of Nephrology: JASN, 2007, 18, 613-620.	3.0	392

#	Article	IF	CITATIONS
340	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 586-593.	0.4	214
341	Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International, 2007, 72, 1130-1137.	2.6	454
342	Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm. Advances in Chronic Kidney Disease, 2007, 14, 3-12.	0.6	228
343	Mineral Metabolism and Mortality in Patients with Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2007, 14, 13-21.	0.6	8
344	Clinical Assessment of Vascular Calcification. Advances in Chronic Kidney Disease, 2007, 14, 37-43.	0.6	29
345	Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment. Journal of Managed Care Pharmacy, 2007, 13, 397-411.	2.2	72
346	Ectopic Mineralization: New Concepts in Etiology and Regulation. , 0, , 349-360.		0
347	Peripheral Vascular Disease in Diabetic Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2007, 27, 210-214.	1.1	11
348	An Overview of the Pathophysiology of Vascular Calcification in Chronic Kidney Disease. Peritoneal Dialysis International, 2007, 27, 215-222.	1.1	39
349	Terapia della iperfosforemia nel paziente uremico: Trattamento farmacologico: qual è il ruolo dei "vecchi―chelanti?. Giornale De Techniche Nefrologiche & Dialitiche, 2007, 19, 8-12.	0.1	0
350	Ageing of the conduit arteries. Journal of Pathology, 2007, 211, 157-172.	2.1	522
351	Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology, 2007, 12, 500-509.	0.7	71
352	Mineral metabolism disturbances in patients with chronic kidney disease. European Journal of Clinical Investigation, 2007, 37, 607-622.	1.7	46
353	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Techniques and Technologies to Assess Vascular Calcification. Seminars in Dialysis, 2007, 20, 129-133.	0.7	38
354	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Arterial Calcification in Dialysis Patients and Transplant Recipients. Seminars in Dialysis, 2007, 20, 144-149.	0.7	15
355	<i>Summary and Comment</i> : Arterial Stiffness and Vascular Calcification in Dialysis Patients: New Measures of Cardiovascular Risk. Seminars in Dialysis, 2007, 20, 477-479.	0.7	6
356	Influence of Sevelamer on Mineral Metabolism and Hyperparathyroidism in Japanese Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2007, 11, 210-214.	0.4	4
357	Comparison of Coronary Atherosclerotic Volume in Patients With Glomerular Filtration Rates â‰ø0 Versus >60 ml/min/1.73 m2: A Meta-Analysis of Intravascular Ultrasound Studies. American Journal of Cardiology. 2007. 99. 813-816.	0.7	28

#	Article	IF	CITATIONS
358	Myocardial Perfusion and Ventricular Function Assessed by SPECT and Gated-SPECT in End-Stage Renal Disease Patients before and after Renal Transplant. Archives of Medical Research, 2007, 38, 227-233.	1.5	10
359	Which issues should trials address in hemodialysis?. Hemodialysis International, 2007, 11, S44-S47.	0.4	Ο
360	Vascular Calcification and Fetuin-A Deficiency in Chronic Kidney Disease. Trends in Cardiovascular Medicine, 2007, 17, 124-128.	2.3	63
361	Temporary Worsening of Renal Function After Aortic Surgery Is Associated With Higher Long-Term Mortality. American Journal of Kidney Diseases, 2007, 50, 219-228.	2.1	57
362	Effect of 2-Methylene-19-nor-(20S)-1α-Hydroxy-Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. Journal of Bone and Mineral Research, 2007, 22, 686-694.	3.1	14
363	Differential Effects of Vitamin D Analogs on Vascular Calcification. Journal of Bone and Mineral Research, 2007, 22, 860-866.	3.1	150
364	Treatment of renal osteodystrophy. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 27-38.	1.3	2
366	Atherosclerotic risk factors and carotid stiffness in elderly asymptomatic HD patients. International Urology and Nephrology, 2007, 38, 801-809.	0.6	16
367	Bone health and vascular calcification relationships in chronic kidney disease. International Urology and Nephrology, 2007, 39, 1209-1216.	0.6	36
368	Evaluation of aortic stiffness in children with chronic renal failure. Pediatric Nephrology, 2007, 22, 1911-1919.	0.9	8
369	To what extent can coronary calcification and arterial stiffness be influenced by the nephrologist?. Clinical Research in Cardiology Supplements, 2007, 2, S15-S21.	2.0	0
370	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. International Journal of Cardiovascular Imaging, 2008, 24, 645-671.	0.7	94
371	Bone and mineral disorders in pre-dialysis CKD. International Urology and Nephrology, 2008, 40, 427-440.	0.6	66
372	Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. International Urology and Nephrology, 2008, 40, 1067-1074.	0.6	27
373	Arterial structure and function in end-stage renal disease. Current Hypertension Reports, 2008, 10, 107-111.	1.5	36
374	Determinants of the intima–media thickness in children and adolescents with chronic kidney disease. Pediatric Nephrology, 2008, 23, 805-811.	0.9	29
375	Circulating calcification inhibitors and vascular properties in children after renal transplantation. Pediatric Nephrology, 2008, 23, 985-993.	0.9	24
376	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. European Radiology, 2008, 18, 2785-2807.	2.3	93

#	Article	IF	CITATIONS
377	Effects of Serum Calcium, Phosphorous, and Intact Parathyroid Hormone Levels on Survival in Chronic Hemodialysis Patients in Japan. Therapeutic Apheresis and Dialysis, 2008, 12, 49-54.	0.4	88
378	Intravenous Alfacalcidol Once Weekly Suppresses Parathyroid Hormone in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2008, 12, 137-142.	0.4	4
379	Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients. Therapeutic Apheresis and Dialysis, 2008, 12, 514-525.	0.4	164
381	Calcification in CKD: No Closer to the Cure. American Journal of Kidney Diseases, 2008, 51, 877-879.	2.1	5
382	A Model of the Kinetics of Lanthanum in Human??Bone, Using Data Collected during the Clinical Development of the Phosphate Binder Lanthanum Carbonate. Clinical Pharmacokinetics, 2008, 47, 543-552.	1.6	23
383	Induction of calcification by serum depletion in cell culture: a model for focal calcification in aortas related to atherosclerosis. Lipids in Health and Disease, 2008, 7, 2.	1.2	4
384	Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nature Clinical Practice Nephrology, 2008, 4, 672-681.	2.0	147
385	Salivary Phosphate Secretion in Chronic Kidney Disease. , 2008, 18, 87-90.		37
386	New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opinion on Pharmacotherapy, 2008, 9, 795-811.	0.9	17
387	Associated Risk Factors for Abnormal Ankle-brachial Index in Hemodialysis Patients in a Hospital. Kaohsiung Journal of Medical Sciences, 2008, 24, 473-480.	0.8	13
388	Phosphate Levels and Blood Pressure in Incident Hemodialysis Patients: A Longitudinal Study. Advances in Chronic Kidney Disease, 2008, 15, 321-331.	0.6	10
389	Battleground. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 168-173.	2.2	38
390	Effects of Sevelamer and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients: Results of a Randomized Clinical Trial. , 2008, 18, 91-98.		56
391	Phosphate Is a Uremic Toxin. , 2008, 18, 27-32.		25
392	Chapter 6 Vascular Calcification Inhibitors In Relation To Cardiovascular Disease With Special Emphasis On Fetuinâ€A In Chronic Kidney Disease. Advances in Clinical Chemistry, 2008, 46, 217-262.	1.8	30
393	A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrology Dialysis Transplantation, 2008, 24, 997-1002.	0.4	84
394	Long-Term Effect of Different Dialysate Calcium Concentrations on Parathyroid Hormone Levels in Hemodialysis Patients. Renal Failure, 2008, 30, 943-951.	0.8	4
395	A New Paradigm for the Treatment of Secondary Hyperparathyroidism. CKJ: Clinical Kidney Journal, 2008, 1, i24-i28.	1.4	3

#	Article	IF	CITATIONS
396	Association of Bone Activity, Calcium Load, Aortic Stiffness, and Calcifications in ESRD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1827-1835.	3.0	251
397	Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 836-843.	2.2	71
398	Effects of Sevelamer on the Progression of Vascular Calcification in Patients on Chronic Haemodialysis. Nephron Clinical Practice, 2008, 108, c278-c283.	2.3	59
399	A Review Article: Sevelamer Hydrochloride and Metabolic Acidosis in Dialysis Patients. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 283-286.	0.2	6
400	Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 24, 239-246.	0.4	118
401	Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrology Dialysis Transplantation, 2008, 24, 948-955.	0.4	190
402	Controversies in chronic kidney disease, anaemia and cardiovascular disease. British Journal of Hospital Medicine (London, England: 2005), 2008, 69, 580-586.	0.2	2
403	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney International, 2008, 74, 265-275.	2.6	40
404	Residual Renal Function – One of the Factors Associated with Arterial Stiffness in Peritoneal Dialysis Patients. Blood Purification, 2008, 26, 133-137.	0.9	27
405	The Prevalence of Carotid Artery Calcification on the Panoramic Radiographs of End-stage Renal Disease Patients with Peritoneal Dialysis: Do Incidental Findings Provide Life-saving Information?. Journal of International Medical Research, 2008, 36, 47-53.	0.4	12
406	Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics. CKJ: Clinical Kidney Journal, 2008, 1, i29-i35.	1.4	6
407	Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney International, 2008, 74, S38-S43.	2.6	16
408	Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney International, 2008, 74, S50-S54.	2.6	23
409	Renal function and structure in a rat model of arterial calcification and increased pulse pressure. American Journal of Physiology - Renal Physiology, 2008, 295, F1222-F1229.	1.3	6
410	Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder. Journal of Pharmacy Practice, 2008, 21, 196-213.	0.5	2
411	Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1718-1725.	2.2	152
412	Interstitial acidosis around the collecting ducts in dRTA. Kidney International, 2008, 73, 1094-1095.	2.6	0
413	IL-18 is involved in vascular injury in end-stage renal disease patients. Nephrology Dialysis Transplantation, 2008, 24, 589-596.	0.4	37

#	Article	IF	CITATIONS
414	25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 24, 611-618.	0.4	81
415	Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney International, 2008, 73, 407-414.	2.6	98
416	Aortic Arch Calcification and Arterial Stiffness are Independent Factors for Diastolic Left Ventricular Dysfunction in Chronic Hemodialysis Patients. Circulation Journal, 2008, 72, 1768-1772.	0.7	52
417	New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease. Recent Patents on Cardiovascular Drug Discovery, 2008, 3, 222-228.	1.5	5
418	Response to â€~Lack of mortality benefit with sevelamer'. Kidney International, 2008, 73, 1093-1094.	2.6	1
419	Assessment and significance of arterial stiffness in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2008, 17, 635-641.	1.0	102
420	Accelerated arterial stiffening and gene expression profile of the aorta in patients with coronary artery disease. Journal of Hypertension, 2008, 26, 747-757.	0.3	26
422	Clinical Factors Associated with Brachial-Ankle Pulse Wave Velocity in Patients on Maintenance Hemodialysis. Electrolyte and Blood Pressure, 2008, 6, 61.	0.6	7
423	Bone Mineral Density, Vascular Calcifications, and Arterial Stiffness in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 668-672.	1.1	21
425	Styloid Process Elongation or Eagle's Syndrome: Is There Any Role for Ectopic Calcification?. European Journal of Dentistry, 2008, 02, 224-228.	0.8	27
426	Arterial Stiffness in Patients with Non-Diabetic Chronic Kidney Disease (CKD). Journal of Atherosclerosis and Thrombosis, 2009, 16, 57-62.	0.9	31
427	Associations between Oxidized LDL to LDL Ratio, HDL and Vascular Calcification in the Feet of Hemodialysis Patients. Journal of Korean Medical Science, 2009, 24, S115.	1.1	16
428	Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 71-81.	1.5	14
429	Serum Phosphate and Left Ventricular Hypertrophy in Young Adults: The Coronary Artery Risk Development in Young Adults Study. Kidney and Blood Pressure Research, 2009, 32, 37-44.	0.9	41
430	Increased Aortic Wall Stiffness Associated with Low Circulating Fetuin A and High C-Reactive Protein in Predialysis Patients. Nephron Clinical Practice, 2009, 113, c81-c87.	2.3	15
431	Coronary artery calcium distribution and interscan measurement variability in end-stage renal and coronary heart disease patients. Acta Radiologica, 2009, 50, 288-295.	0.5	1
432	Impact of Anemia on Aortic Pulse Wave Velocity in Hemodialysis Patients. Kidney and Blood Pressure Research, 2009, 32, 210-216.	0.9	5
433	Lack of Correlation between Calcium Intake and Serum Calcium Levels in Stable Haemodialysis Subjects. Nephron Clinical Practice, 2009, 113, c162-c168.	2.3	14

#	Article	IF	CITATIONS
434	Upregulation of Matrix Metalloproteinase-2 in the Arterial Vasculature Contributes to Stiffening and Vasomotor Dysfunction in Patients With Chronic Kidney Disease. Circulation, 2009, 120, 792-801.	1.6	102
435	Can dental pulp calcification serve as a diagnostic marker for carotid artery calcification in patients with renal diseases?. Dentomaxillofacial Radiology, 2009, 38, 542-545.	1.3	31
436	Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date?. Nephrology Dialysis Transplantation, 2009, 24, 2970-2972.	0.4	3
437	Does Vascular Calcification Correlate with Pulse Wave Velocity in Hemodialysis Patients?. Nephrology Research & Reviews, 2009, 1, 11-17.	0.2	3
438	The impact of arteriovenous fistulas on aortic stiffness in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 3441-3446.	0.4	18
439	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International, 2009, 76, 705-716.	2.6	87
440	A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2009, 24, 3389-3397.	0.4	60
441	Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Current Medical Research and Opinion, 2009, 25, 3021-3028.	0.9	68
442	Aortic Calcification Is Associated With Aortic Stiffness and Isolated Systolic Hypertension in Healthy Individuals. Hypertension, 2009, 53, 524-531.	1.3	195
443	Is Valvular Calcification a Part of the Missing Link between Residual Kidney Function and Cardiac Hypertrophy in Peritoneal Dialysis Patients?. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1629-1636.	2.2	20
444	Relation of Serum Fetuin-A Levels to Coronary Artery Calcium in African-American Patients on Chronic Hemodialysis. American Journal of Cardiology, 2009, 103, 46-49.	0.7	23
445	Clinical assessment of atherosclerotic parameters and cardiac function in chronic hemodialysis patients. Clinical and Experimental Nephrology, 2009, 13, 651-658.	0.7	10
446	Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients. Hemodialysis International, 2009, 13, 301-306.	0.4	66
447	Coronary calcification and its association with mortality in haemodialysis patients. Nephrology, 2009, 14, 164-170.	0.7	21
448	Relationship between vascular calcification, arterial stiffness and bone mineral density in a crossâ€sectional study of prevalent Australian haemodialysis patients. Nephrology, 2009, 14, 105-112.	0.7	35
449	Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patientâ€level outcomes?. Nephrology, 2009, 14, 416-427.	0.7	6
450	Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology, 2009, 14, 408-415.	0.7	28
451	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients. Geriatrics and Gerontology International, 2009, 9, 246-252.	0.7	36

#	Article	IF	CITATIONS
452	Highâ€Resolution Ultrasound Elasticity Imaging to Evaluate Dialysis Fistula Stenosis. Seminars in Dialysis, 2009, 22, 84-89.	0.7	18
453	Phosphate Binders in Chronic Kidney Disease and Endâ€Stage Renal Disease: A Patientâ€Centered Approach. Seminars in Dialysis, 2009, 22, 56-63.	0.7	1
454	Prevention and Management of Hyperphosphatemia with Sevelamer in Canada: Health and Economic Consequences. Value in Health, 2009, 12, 16-19.	0.1	11
458	Calcification in atherosclerosis. Nature Reviews Cardiology, 2009, 6, 681-688.	6.1	178
460	Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet Hydrochloride. Clinical Pharmacokinetics, 2009, 48, 303-311.	1.6	77
461	Vascular Calcification. Journal of the American Society of Nephrology: JASN, 2009, 20, 1453-1464.	3.0	445
462	La recherche des échos de diffusion en échographie à haute résolution peut détecter les modifications mécaniques de la paroi des pontages artériels périphériques en veine. Annales De Chirurgie Vasculaire, 2009, 23, 218-223.	0.0	0
463	High-resolution Ultrasound Speckle Tracking May Detect Vascular Mechanical Wall Changes in Peripheral Artery Bypass Vein Grafts. Annals of Vascular Surgery, 2009, 23, 201-206.	0.4	13
464	Salivary Phosphorus and Phosphate Content of Beverages: Implications for the Treatment of Uremic Hyperphosphatemia. , 2009, 19, 69-72.		21
465	Fonction artérielle et risque cardiovasculaire. Medecine Des Maladies Metaboliques, 2009, 3, 267-271.	0.1	0
466	Kidney Disease Outcomes Quality Initiative Guidelines for Bone and Mineral Metabolism: Emerging Questions. Seminars in Nephrology, 2009, 29, 105-112.	0.6	12
467	Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thrombosis and Haemostasis, 2009, 101, 359-366.	1.8	85
468	Improvement of Hyperphosphatemia following Patient Education. Journal of Pharmacy Technology, 2009, 25, 3-9.	0.5	5
469	Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients. Reviews on Recent Clinical Trials, 2010, 5, 133-137.	0.4	3
470	Arterial Stiffness As A Therapeutic Target For Isolated Systolic Hypertension: Focus on Vascular Calcification and Fibrosis. Current Hypertension Reviews, 2010, 6, 20-31.	0.5	1
471	Screening of Vascular Calcification in Hemodialysis Patients. Internal Medicine, 2010, 49, 2657-2658.	0.3	0
472	Association of Osteocalcin and Abdominal Aortic Calcification in Older Women: The Study of Osteoporotic Fractures. Calcified Tissue International, 2010, 86, 185-191.	1.5	18
473	When Does the Cardiovascular Disease Appear in Patients With Chronic Kidney Disease?. Pediatric Cardiology, 2010, 31, 821-828.	0.6	10

#	Article	IF	CITATIONS
474	Relation of oral 1α-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart and Vessels, 2010, 25, 1-6.	0.5	21
475	Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatric Nephrology, 2010, 25, 373-375.	0.9	20
476	Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. International Urology and Nephrology, 2010, 42, 187-194.	0.6	47
477	Arterial stiffness in dialysis patients: where are we now?. International Urology and Nephrology, 2010, 42, 741-752.	0.6	51
478	Vascular calcification score on plain radiographs of the feet as a predictor of peripheral arterial disease in patients with chronic kidney disease. International Urology and Nephrology, 2010, 42, 773-780.	0.6	24
479	Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. American Journal of Kidney Diseases, 2010, 56, 57-68.	2.1	99
480	Arterial calcifications. Journal of Cellular and Molecular Medicine, 2010, 14, 2203-2210.	1.6	49
481	Association of Calciumâ€Phosphorus Product With Blood Pressure in Dialysis. Journal of Clinical Hypertension, 2010, 12, 96-103.	1.0	6
482	Estimation of distributed arterial mechanical properties using a wave propagation model in a reverse way. Medical Engineering and Physics, 2010, 32, 957-967.	0.8	39
483	Arterial elasticity imaging: comparison of finite-element analysis models with high-resolution ultrasound speckle tracking. Cardiovascular Ultrasound, 2010, 8, 22.	0.5	13
484	Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. Nephrology, 2010, 15, 184-189.	0.7	20
485	Evaluation of Peripheral Vascular Calcification and Serum Magnesium Level in a Group of Egyptian Hemodialysis Patients. Sudanese Journal of Ophthalmology, 2010, 3, .	0.0	2
486	Impact of Cardiovascular Calcification in Nondialyzed Patients after 24 Months of Follow-up. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 189-194.	2.2	70
487	Cardiovascular Disease in Patients with Chronic Kidney Disease. , 2010, , 128-144.		1
488	Cardiovascular risk in the peritoneal dialysis patient. Nature Reviews Nephrology, 2010, 6, 451-460.	4.1	133
489	Ten-Year Experience with Sevelamer and Calcium Salts as Phosphate Binders. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, S31-S40.	2.2	40
490	Alteraciones del Metabolismo óseo y mineral en enfermedad renal crónica pre-diálisis. Revista Médica ClÃnica Las Condes, 2010, 21, 530-540.	0.2	1
491	Intradialytic exercise training reduces oxidative stress and epicardial fat: a pilot study. Nephrology Dialysis Transplantation, 2010, 25, 2695-2701.	0.4	118

		CITATION REPORT		
#	Article		IF	Citations
492	Early Origins of Cardiovascular Disease in Pediatric Chronic Kidney Disease. Renal Failur	re, 2010, 32, 1-9.	0.8	10
493	The five most cited NDT articles from 1999 to 2004. Nephrology Dialysis Transplantatio 2818-2824.	on, 2010, 25,	0.4	1
494	Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrolog Transplantation, 2010, 25, 574-581.	with y Dialysis	0.4	22
495	Vascular calcification in chronic kidney disease. Clinical Science, 2010, 119, 111-121.		1.8	88
496	Ironing out the phosphorus problem. Kidney International, 2010, 77, 845-847.		2.6	3
497	The Effect of Sevelamer Hydrochloride and Calcium-Based Phosphate Binders on Morta Hemodialysis Patients: A Need for More Research. The Consultant Pharmacist, 2010, 2	lity in 5, 41-54.	0.4	3
498	Factors associated with aortic stiffness and its change over time in peritoneal dialysis p Nephrology Dialysis Transplantation, 2010, 25, 4041-4048.	atients.	0.4	42
499	Atherosclerosis in CKD: differences from the general population. Nature Reviews Nephr 723-735.	ology, 2010, 6,	4.1	174
500	Osteoprotegerin and Progression of Coronary and Aortic Calcifications in Chronic Kidn Transplantation Proceedings, 2010, 42, 3444-3449.	ey Disease.	0.3	12
501	Awareness of Vascular Calcification Alters Mineral Metabolism Management. Seminars 2010, 23, 267-270.	in Dialysis,	0.7	5
502	Methods and potential biomarkers for the evaluation of endothelial dysfunction in chro disease: A critical approach. Journal of the American Society of Hypertension, 2010, 4,	nic kidney 116-127.	2.3	38
503	Bone morphogenetic protein-2 may represent the molecular link between oxidative strovascular stiffness in chronic kidney disease. Atherosclerosis, 2010, 211, 418-423.	ess and	0.4	56
504	Roles of Calcium-Sensing Receptor and Vitamin D Receptor in the Pathophysiology of S Hyperparathyroidism. , 2010, 20, 141-150.	jecondary		20
505	Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 575-582.	s patients.	0.6	34
506	Intravenous Alfacalcidol Once Weekly Pulse Therapy for Secondary Hyperparathyroidis Hemodialysis Patients. Renal Failure, 2011, 33, 329-333.	n in	0.8	1
507	Noninvasive imaging for assessment of calcification in chronic kidney disease. Nature R Nephrology, 2011, 7, 567-577.	leviews	4.1	54
508	Derangements in Phosphate Metabolism in Chronic Kidney Diseases/Endstage Renal Di Considerations. Advances in Chronic Kidney Disease, 2011, 18, 120-131.	sease: Therapeutic	0.6	32
509	Salivary Glands: A New Player in Phosphorus Metabolism. , 2011, 21, 39-42.			22

#	Article	IF	CITATIONS
510	Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney International, 2011, 79, 1071-1079.	2.6	177
511	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 1327-1339.	0.4	491
512	Serum Fibroblast Growth Factor-23 Levels and Progression of Aortic Arch Calcification in Non-Diabetic Patients on Chronic Hemodialysis. Journal of Atherosclerosis and Thrombosis, 2011, 18, 217-223.	0.9	34
513	The relationship between calcium metabolism, insulin-like growth factor-1 and pulse pressure in normotensive, normolipidaemic and non-diabetic patients. Archives of Medical Science, 2011, 5, 776-780.	0.4	3
514	Prevalência e correlatos de doença vascular no exame de ultrassom em pacientes em hemodiálise. Arquivos Brasileiros De Cardiologia, 2011, 96, 260-265.	0.3	3
515	Serum levels of advanced glycation end-products in hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2011, 44, 1015-1021.	0.2	0
516	Phosphate Binding Capacities of Therapeutic Agents for Hyperphosphatemia. Iryo Yakugaku (Japanese) Tj ETQqO (0 0 rgBT /0	Overlock 10

517	Age-related and blood pressure-independent reduction in aortic stiffness after kidney transplantation. Journal of Hypertension, 2011, 29, 130-136.	0.3	39
518	Relationship between coronary artery plaque composition by virtual histology intravascular ultrasound analysis and brachial-ankle pulse wave velocity in patients with coronary artery disease. Coronary Artery Disease, 2011, 22, 565-569.	0.3	9
519	Impact of Statins on Cardiovascular Outcomes in Renal Transplant Recipients: A Systematic Review. American Journal of Therapeutics, 2011, 18, e48-e54.	0.5	3
521	Aortic Arch Calcification and Clinical Outcome in Patients with End-Stage Renal Disease. Tohoku Journal of Experimental Medicine, 2011, 223, 79-84.	0.5	17
522	Attenuation of aortic calcification with lanthanum carbonate <i>versus</i> calciumâ€based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology, 2011, 16, 290-298.	0.7	109
523	Comparison of vascular calcification scoring systems using plain radiographs to predict vascular stiffness in peritoneal dialysis patients. Nephrology, 2011, 16, no-no.	0.7	5
524	Efficacy and safety of SBR759, a novel calciumâ€free, iron(III)â€based phosphate binder, in Asian patients undergoing hemodialysis: A 12â€week, randomized, openâ€label, doseâ€titration study <i>versus</i> sevelamer hydrochloride. Nephrology, 2011, 16, 743-750.	0.7	23
525	Use of cardioâ€ankle vascular index in chronic dialysis patients. European Journal of Clinical Investigation, 2011, 41, 45-51.	1.7	11
526	Fetuin-A serum levels in patients with aortic aneurysms of Marfan syndrome and atherosclerosis. European Journal of Clinical Investigation, 2011, 41, 176-182.	1.7	8
527	Effects of Aortic Stiffness Abnormalities on the Heart. Seminars in Dialysis, 2011, 24, 282-285.	0.7	4
528	Intracranial arterial calcification is highly prevalent in hemodialysis patients but does not associate with acute ischemic stroke. Hemodialysis International, 2011, 15, 256-263.	0.4	15

#	Article	IF	CITATIONS
529	Elevated parathyroid hormone predicts mortality in dialysis patients undergoing valve surgery. Surgery, 2011, 150, 1095-1101.	1.0	11
530	Effect of Sevelamer and Calcium-Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Clycation End Products in Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 57, 422-431.	2.1	128
531	Aortic Stiffness and Vitamin D are Independent Markers of Aortic Calcification in Patients with Peripheral Arterial Disease and in Healthy Subjects. European Journal of Vascular and Endovascular Surgery, 2011, 42, 689-695.	0.8	48
532	Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Failure Reviews, 2011, 16, 615-620.	1.7	74
533	Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clinical and Experimental Nephrology, 2011, 15, 877-883.	0.7	43
534	Serum level of soluble Hsp70 is associated with vascular calcification. Cell Stress and Chaperones, 2011, 16, 257-265.	1.2	37
535	Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study. BMC Nephrology, 2011, 12, 56.	0.8	13
536	Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome Science, 2011, 9, 25.	0.7	45
537	Analysis of some risk factors of coronary and valvular calcification in peritoneal dialysis. Dialysis and Transplantation, 2011, 40, 118-122.	0.2	1
538	Pathologic calcification of adult vascular smooth muscle cells differs on their crest or mesodermal embryonic origin. Journal of Bone and Mineral Research, 2011, 26, 1543-1553.	3.1	89
539	Fenestration of a Gore Helex Septal Occluder device in a patient with diastolic dysfunction of the left ventricle. Catheterization and Cardiovascular Interventions, 2011, 78, 594-598.	0.7	11
540	Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrology Dialysis Transplantation, 2011, 26, 2250-2256.	0.4	77
541	Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism. Journal of International Medical Research, 2011, 39, 978-987.	0.4	25
542	β2-Microglobulin, Pulse Pressure and Metabolic Alterations in Hemodialysis Patients. Nephron Clinical Practice, 2011, 117, c237-c245.	2.3	20
543	Association between Very Low PTH Levels and Poor Survival Rates in Haemodialysis Patients: Results from the French ARNOS Cohort. Nephron Clinical Practice, 2011, 118, c211-c216.	2.3	35
544	Soft Bone – Hard Arteries: A Link. Kidney and Blood Pressure Research, 2011, 34, 203-208.	0.9	20
545	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Therapeutic Advances in Chronic Disease, 2011, 2, 265-278.	1.1	25
546	Effect of Sevelamer Hydrochloride Exposure on Carotid Intima Media Thickness in Hemodialysis Patients. Nephron Clinical Practice, 2011, 117, c83-c88.	2.3	12

#	Article	IF	Citations
547	Coronary Artery Calcification Progression Is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients. Kidney and Blood Pressure Research, 2011, 34, 180-187.	0.9	42
548	Vascular and Valvular Calcification in Chronic Peritoneal Dialysis Patients. International Journal of Nephrology, 2011, 2011, 1-9.	0.7	22
549	Vascular Calcification Is Associated with Cortical Bone Loss in Chronic Renal Failure Rats with and without Ovariectomy: The Calcification Paradox. American Journal of Nephrology, 2011, 34, 356-366.	1.4	27
550	The dualistic role of vitamin D in vascular calcifications. Kidney International, 2011, 79, 708-714.	2.6	124
551	Arterial elasticity as a predictor for arteriovenous fistula maturation: Preliminary results. , 2011, , .		1
552	Superficial temporal artery calcification in patients with end-stage renal disease: Association with vascular risk factors and ischemic cerebrovascular disease. Indian Journal of Radiology and Imaging, 2011, 21, 215.	0.3	2
553	Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification. International Journal of Nephrology, 2011, 2011, 1-8.	0.7	15
554	Pulmonary Function is Associated with Distal Aortic Calcium, Not Proximal Aortic Distensibility. MESA Lung Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 71-78.	0.7	16
555	Vascular calcification and hypertension: Cause and effect. Annals of Medicine, 2012, 44, S85-S92.	1.5	91
556	Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrology Dialysis Transplantation, 2012, 27, 1957-1966.	0.4	156
557	The Prevalence of Hypertension, Valve Calcification and Left Ventricular Hypertrophy and Geometry in Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 431-437.	0.9	11
558	Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney International, 2012, 82, 34-44.	2.6	127
559	Mineral and Bone Disease in Black African Hemodialysis Patients: A Report From Senegal. Nephro-Urology Monthly, 2012, 4, 613-616.	0.0	13
560	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. American Journal of Nephrology, 2012, 35, 24-30.	1.4	13
561	Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure. Nephrology Dialysis Transplantation, 2012, 27, 4166-4172.	0.4	46
562	Ultrasound Measurement of Brachial Artery Elasticity Prior to Hemodialysis Access Placement. Journal of Ultrasound in Medicine, 2012, 31, 1581-1588.	0.8	18
563	Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology, 2012, 78, 216-223.	0.4	20
564	Increasing Prevalence of Peripheral Artery Occlusive Disease in Hemodialysis Patients: A 2-Year Follow-Up. American Journal of the Medical Sciences, 2012, 343, 440-445.	0.4	13

#	Article	IF	Citations
565	Risk Factors Associated with Coronary Artery Calcification Should Be Examined before Kidney Transplantation. Tohoku Journal of Experimental Medicine, 2012, 226, 137-144.	0.5	5
566	Involvement of parathyroid hormoneâ€related protein in vascular calcification of chronic haemodialysis patients. Nephrology, 2012, 17, 552-560.	0.7	7
567	Intima media thickness in children undergoing dialysis. Pediatric Nephrology, 2012, 27, 1557-1564.	0.9	12
568	Hypervolemia rather than arterial calcification and extracoronary atherosclerosis is the main determinant of pulse pressure in hemodialysis patients. International Urology and Nephrology, 2012, 44, 1203-1210.	0.6	5
569	Dysregulated gene expression of extracellular matrix and adhesion molecules in saphenous vein conduits of hemodialysis patients. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 684-689.	0.4	5
571	Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrology Dialysis Transplantation, 2012, 27, 4298-4307.	0.4	25
572	Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrology Dialysis Transplantation, 2012, 27, 990-996.	0.4	37
573	Lanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding. Renal Failure, 2012, 34, 263-270.	0.8	13
574	Increased Levels of Serum Parathyroid Hormone and Fibroblast Growth Factor-23 Are the Main Factors Associated with the Progression of Vascular Calcification in Long-Hour Hemodialysis Patients. Nephron Clinical Practice, 2012, 120, c132-c138.	2.3	43
575	Arterial stiffness and pulse pressure in CKD and ESRD. Kidney International, 2012, 82, 388-400.	2.6	307
576	Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?. Expert Opinion on Pharmacotherapy, 2012, 13, 2255-2256.	0.9	0
577	Juvenile elastic arteries after 28 years of renal replacement therapy in a patient with complete complement C4 deficiency. BMC Nephrology, 2012, 13, 161.	0.8	4
578	Nonocclusive Mesenteric Ischemia in a Dialysis Patient With Extensive Vascular Calcification. American Journal of Kidney Diseases, 2012, 60, 843-846.	2.1	13
579	Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney International, 2012, 82, 19-25.	2.6	63
580	Visceral Fat Thickness Is Associated With Carotid Atherosclerosis in Peritoneal Dialysis Patients. Obesity, 2012, 20, 1301-1307.	1.5	23
581	Bone-vascular cross-talk. Journal of Nephrology, 2012, 25, 619-625.	0.9	52
582	Aortic Calcification and Femoral Bone Density Are Independently Associated with Left Ventricular Mass in Patients with Chronic Kidney Disease. PLoS ONE, 2012, 7, e39241.	1.1	10
583	Abdominal Aortic Calcification is Associated with Diastolic Dysfunction, Mortality, and Nonfatal Cardiovascular Events in Maintenance Hemodialysis Patients. Journal of Korean Medical Science, 2012, 27, 870.	1.1	23

#	Article	IF	CITATIONS
584	The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. International Urology and Nephrology, 2012, 44, 601-606.	0.6	41
585	Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients. Heart and Vessels, 2012, 27, 135-142.	0.5	48
586	Vitamin D and Stage 5 Chronic Kidney Disease: A New Paradigm?. Seminars in Dialysis, 2012, 25, 50-58.	0.7	12
587	Improved Long-Term Survival of Dialysis Patients after Near-Total Parathyroidectomy. Journal of the American College of Surgeons, 2012, 214, 400-407.	0.2	85
588	Left ventricular mass index and aortic arch calcification score are independent mortality predictors of maintenance hemodialysis patients. Hemodialysis International, 2012, 16, 504-511.	0.4	17
589	Cardiovascular risk assessment in children following kidney transplantation. Pediatric Transplantation, 2012, 16, 564-576.	0.5	20
590	Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients. International Urology and Nephrology, 2012, 44, 255-262.	0.6	17
591	Integration of clinical and imaging data to predict death in hemodialysis patients. Hemodialysis International, 2013, 17, 12-18.	0.4	10
592	Anatomic Brain Disease in Hemodialysis Patients: A Cross-sectional Study. American Journal of Kidney Diseases, 2013, 61, 271-278.	2.1	103
593	Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney International, 2013, 83, 1109-1117.	2.6	59
594	Clinical Practice Guideline for the Management of Chronic Kidney Diseaseâ€Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 2013, 17, 247-288.	0.4	305
595	Prospective analysis of coronary calcium in patients on dialysis undergoing a near-total parathyroidectomy. Surgery, 2013, 154, 1315-1322.	1.0	19
596	Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrology Dialysis Transplantation, 2013, 28, 1874-1888.	0.4	24
597	Cerebral oximetry in cardiovascular dialysis patients. Hellenike Cheirourgike Acta Chirurgica Hellenica, 2013, 85, 328-332.	0.1	0
598	Potential beneficial role of sevelamer hydrochloride in diabetic retinopathy. Medical Hypotheses, 2013, 80, 431-435.	0.8	5
599	Effect of serum <scp>FGF</scp> â€23, <scp>MGP</scp> and fetuinâ€ <scp>A</scp> on calciumâ€phosphate metabolism in maintenance hemodialysis patients. Hemodialysis International, 2013, 17, 483-492.	0.4	6
600	Optimal Nutrition for Predialysis Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2013, 20, 175-180.	0.6	15
602	Alkaline phosphatase and arterial structure and function in hypertensive African men: The SABPA study. International Journal of Cardiology, 2013, 167, 1995-2001.	0.8	15

#	Article	IF	CITATIONS
603	Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease. American Journal of Nephrology, 2013, 37, 191-198.	1.4	35
604	Cardiovascular Effects of Sevelamer in Stage 3 CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 842-852.	3.0	108
605	Advanced Glycation End Products-induced Vascular Calcification is Mediated by Oxidative Stress: Functional Roles of NAD(P)H-oxidase. Hormone and Metabolic Research, 2013, 45, 267-272.	0.7	39
606	Phosphate Toxicity and Vascular Mineralization. Contributions To Nephrology, 2013, 180, 74-85.	1.1	41
607	Determinants of Progression of Aortic Stiffness in Hemodialysis Patients. Hypertension, 2013, 62, 154-160.	1.3	82
608	Lanthanum Carbonate Delays Progression of Coronary Artery Calcification Compared With Calcium-Based Phosphate Binders in Patients on Hemodialysis. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 439-446.	1.0	38
609	Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating NF-κB and down-regulating IGF1R expression. Acta Pharmacologica Sinica, 2013, 34, 480-486.	2.8	19
610	Associations between Pulse Wave Velocity, Aortic Vascular Calcification, and Bone Mineral Density in Chronic Hemodialysis Patients and General Population. ISRN Vascular Medicine, 2013, 2013, 1-9.	0.7	1
611	Vascular Calcifications, Arterial Aging and Arterial Remodeling in ESRD. Blood Purification, 2013, 35, 16-21.	0.9	27
612	Chronic Hemodialysis Patients Without Marked Elevation of Intact Parathyroid Hormone Are Also Good Candidates for Early Intervention With Cinacalcet. Therapeutic Apheresis and Dialysis, 2013, 17, 325-331.	0.4	0
613	Vascular calcification in endâ€stage renal disease. Hemodialysis International, 2013, 17, S17-21.	0.4	78
614	Low serum fetuin A levels and incident stroke in patients with maintenance haemodialysis. European Journal of Clinical Investigation, 2013, 43, 387-396.	1.7	13
615	Arterial Stiffness Depends on Serum Ionized Calcium Levels During Dialysis With Regional Citrate Anticoagulation. Artificial Organs, 2013, 37, 467-474.	1.0	10
616	A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. Journal of Medical Economics, 2013, 16, 1-9.	1.0	27
617	Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney International, 2013, 84, 1145-1153.	2.6	52
618	Mechanisms of arterial calcifications and consequences for cardiovascular function. Kidney International Supplements, 2013, 3, 442-445.	4.6	42
619	Arteriovenous access failure: more than just intimal hyperplasia?. Nephrology Dialysis Transplantation, 2013, 28, 1085-1092.	0.4	110
620	Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management. Journal of Cardiovascular Medicine, 2013, 14, 410-415.	0.6	4

		CITATION RE	PORT	
#	Article		IF	CITATIONS
621	Mineral Metabolic Abnormalities and Mortality in Dialysis Patients. Nutrients, 2013, 5, 10)02-1023.	1.7	36
622	Parathyroidectomy Improves Survival In Patients with Severe Hyperparathyroidism: A Co Study. PLoS ONE, 2013, 8, e68870.	mparative	1.1	58
623	Site and Size of Vascular Calcifications Are Different in Dialysis Patients with Various Uno Diseases. , 2013, , .	lerlying		0
624	Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future res needs. World Journal of Nephrology, 2014, 3, 156.	earch	0.8	79
625	Calcium Balance and Negative Impact of Calcium Load in Peritoneal Dialysis Patients. Per Dialysis International, 2014, 34, 345-352.	itoneal	1.1	25
626	Estimated glomerular filtration rate is associated with both arterial stiffness and N-termin pro-brain natriuretic peptide in newly diagnosed hypertensive patients. Clinical and Expe Hypertension, 2014, 36, 374-379.	nal rimental	0.5	2
627	An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal Nephrology, 2014, 2014, 1-9.	of	0.7	59
628	Neurological Disorders in a Murine Model of Chronic Renal Failure. Toxins, 2014, 6, 180-	193.	1.5	10
629	The association between mortality and abdominal aortic calcification and relation betwe progression and serum calcium concentration in chronic hemodialysis patients. Kidney R Clinical Practice, 2014, 33, 95-102.	en its esearch and	0.9	19
630	Clinical Effects of Longâ€Term (36â€Month) Lanthanum Carbonate Administration in He in <scp>J</scp> apan. Therapeutic Apheresis and Dialysis, 2014, 18, 9-13.	modialysis Patients	0.4	4
632	Increased Aortic Stiffness Predicts Contrast-Induced Nephropathy in Patients With Stabl Artery Disease Undergoing Percutaneous Coronary Intervention. Angiology, 2014, 65, 80	e Coronary)6-811.	0.8	10
633	The effects of non-calcium-based phosphate binders versus calcium-based phosphate bir cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysi randomized trials. Renal Failure, 2014, 36, 1244-1252.	ders on s of	0.8	25
634	Renal function, uraemia and early arteriovenous fistula failure. BMC Nephrology, 2014, 1	5, 179.	0.8	19
635	The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrology Dialysis Transp 29, 1061-1073.	plantation, 2014,	0.4	25
636	Convective Versus Diffusive Dialysis Therapies for Chronic Kidney Failure: An Updated Sy Review of Randomized Controlled Trials. American Journal of Kidney Diseases, 2014, 63,	stematic 954-967.	2.1	113
637	Renal Artery Calcium, Cardiovascular Risk Factors, and Indexes of Renal Function. Americ of Cardiology, 2014, 113, 156-161.	an Journal	0.7	23
638	Dietary and Pharmacological Modification of Fibroblast Growth Factor-23 in Chronic Kidr 2014, 24, 143-150.	iey Disease. ,		16
639	Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, ver chronic kidney disease stage V Japanese patients on maintenance renal replacement the and Experimental Nephrology, 2014, 18, 135-143.	sus placebo in rapy. Clinical	0.7	10

	СПАНО	N KLPOKI	
#	Article	IF	CITATIONS
640	Active Vitamin D and Accelerated Progression of Aortic Stiffness in Hemodialysis Patients: A Longitudinal Observational Study. American Journal of Hypertension, 2014, 27, 1346-1354.	1.0	8
641	Phosphate: an old bone molecule but new cardiovascular risk factor. British Journal of Clinical Pharmacology, 2014, 77, 39-54.	1.1	20
642	Serum Calcification Propensity Predicts All-Cause Mortality in Predialysis CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 339-348.	3.0	198
643	Evaluation of Aortic Calcification With Lanthanum Carbonate vs. Calciumâ€Based Phosphate Binders in Maintenance Hemodialysis Patients With Type 2 Diabetes Mellitus: An Openâ€Label Randomized Controlled Trial. Therapeutic Apheresis and Dialysis, 2014, 18, 353-360.	0.4	28
644	Glomerular Filtration Rate is Associated With Burden of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. Angiology, 2014, 65, 350-356.	0.8	10
646	Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opinion on Drug Safety, 2014, 13, 551-561.	1.0	47
647	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. , 2014, , .		20
648	Association of calcium concentration with pulse pressure in older women: Data from a large population-based multicentric study. Journal of Nutrition, Health and Aging, 2014, 18, 323-329.	1.5	10
649	Effect of the arteriovenous access for hemodialysis on subendocardial viability ratio, pulse pressure and hospitalizations. Journal of Nephrology, 2014, 27, 563-570.	0.9	7
650	The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal study. Nephrology Dialysis Transplantation, 2014, 29, 2113-2120.	0.4	37
651	Clinical Effects of the New Phosphorus Binder, Bixalomer in Hemodialysis Patients Switched From Sevelamer Hydrochloride. Therapeutic Apheresis and Dialysis, 2014, 18, 8-12.	0.4	4
652	Lipids in health and disease. Nature, 2014, 510, 47-47.	13.7	24
653	Stroke and renal dysfunction. European Journal of Internal Medicine, 2014, 25, 18-24.	1.0	21
654	Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opinion on Pharmacotherapy, 2014, 15, 1475-1488.	0.9	6
655	Acid-Base Balance in Uremic Rats with Vascular Calcification. Nephron Extra, 2014, 4, 89-94.	1.1	4
656	Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. The Cochrane Library, 2015, 2015, CD006258.	1.5	61
657	Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. Nephrology, 2015, 20, 250-256.	0.7	3
658	Calcium and Sudden Cardiac Death in Endâ€Stage Renal Disease. Seminars in Dialysis, 2015, 28, 624-635.	0.7	11

#	Article	IF	CITATIONS
659	Epicardial adipose tissue in patients with end-stage renal disease on haemodialysis. Current Opinion in Nephrology and Hypertension, 2015, 24, 517-524.	1.0	10
660	Association Studies of Calcium-Sensing Receptor (CaSR) Polymorphisms with Serum Concentrations of Glucose and Phosphate, and Vascular Calcification in Renal Transplant Recipients. PLoS ONE, 2015, 10, e0119459.	1.1	15
661	Link between Peripheral Artery Disease and Heart Rate Variability in Hemodialysis Patients. PLoS ONE, 2015, 10, e0120459.	1.1	10
662	Importance of Abnormal Bone Metabolism in the Acceleration of Atherosclerosis in Hemodialysis Patients. Contributions To Nephrology, 2015, 185, 15-21.	1.1	2
663	The Contribution of Osteoprogenitor Cells to Arterial Stiffness and Hypertension. Journal of Vascular Research, 2015, 52, 32-40.	0.6	14
664	The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Therapeutic Advances in Chronic Disease, 2015, 6, 84-96.	1.1	46
665	Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients. Nephrology Dialysis Transplantation, 2016, 31, gfv402.	0.4	31
666	Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats. American Journal of Physiology - Renal Physiology, 2015, 308, F309-F319.	1.3	12
667	Correlation between conjunctival and corneal calcification and cardiovascular calcification in patients undergoing maintenance hemodialysis. Hemodialysis International, 2015, 19, 270-278.	0.4	5
668	Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Expert Review of Endocrinology and Metabolism, 2015, 10, 131-142.	1.2	1
669	Imaging of haemodialysis: renal and extrarenal findings. Insights Into Imaging, 2015, 6, 309-321.	1.6	21
670	Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology, 2015, 28, 593-602.	0.9	11
671	Upper limb vascular calcification score as a predictor of mortality in diabetic hemodialysis patients. Journal of Vascular Surgery, 2015, 61, 1529-1537.	0.6	16
672	Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. Nephron, 2015, 130, 229-238.	0.9	7
673	Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study. American Journal of Kidney Diseases, 2015, 66, 655-665.	2.1	39
674	Changes in Pulse Pressure during Hemodialysis Treatment and Survival in Maintenance Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1179-1191.	2.2	22
675	Teriparatide Therapy Reduces Serum Phosphate and Intima-Media Thickness at the Carotid Wall Artery in Patients with Osteoporosis. Calcified Tissue International, 2015, 97, 32-39.	1.5	9
676	Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect. International Journal of Pharmaceutics, 2015, 482, 21-26.	2.6	8

#	Article	IF	CITATIONS
677	Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders. Expert Review of Cardiovascular Therapy, 2015, 13, 489-499.	0.6	2
678	Arterial Disorders. , 2015, , .		2
679	Assessment of the relationship between selected cardiovascular risk factors and the indices of intima-media thickness and coronary artery calcium score in various stages of chronic kidney disease. International Urology and Nephrology, 2015, 47, 2003-2012.	0.6	8
680	Mineral (Mal)Adaptation to Kidney Disease—Young Investigator Award Address. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1875-1885.	2.2	28
681	Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis. Journal of Bone and Mineral Metabolism, 2015, 33, 213-220.	1.3	4
683	Bone Strength and Arterial Stiffness Impact on Cardiovascular Mortality in a General Population. Journal of Osteoporosis, 2016, 2016, 1-10.	0.1	17
684	Fruit Intake and Abdominal Aortic Calcification in Elderly Women: A Prospective Cohort Study. Nutrients, 2016, 8, 159.	1.7	26
685	High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity. PLoS ONE, 2016, 11, e0151508.	1.1	30
686	Association of Brachial-Ankle Pulse Wave Velocity and Cardiomegaly With Aortic Arch Calcification in Patients on Hemodialysis. Medicine (United States), 2016, 95, e3643.	0.4	13
687	Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients. American Journal of Transplantation, 2016, 16, 204-212.	2.6	74
688	Therapeutic potential of FGF21 in cardiorenal syndrome. International Journal of Cardiology, 2016, 214, 70-71.	0.8	1
689	Calcium Phosphate Crystals from Uremic Serum Promote Osteogenic Differentiation in Human Aortic Smooth Muscle Cells. Calcified Tissue International, 2016, 99, 543-555.	1.5	13
690	Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia. Blood Purification, 2016, 41, 247-253.	0.9	6
691	Association of Ankle-Brachial Index and Aortic Arch Calcification with Overall and Cardiovascular Mortality in Hemodialysis. Scientific Reports, 2016, 6, 33164.	1.6	10
692	Association between vascular calcification assessed by simple radiography and non-fatal cardiovascular events in hemodialysis patients. Nephrologie Et Therapeutique, 2016, 12, 503-507.	0.2	3
693	Levels of Serum Phosphorus and Cardiovascular Surrogate Markers. Journal of Atherosclerosis and Thrombosis, 2016, 23, 95-104.	0.9	9
694	Reproducibility of Carotid-Femoral Pulse Wave Velocity in End-Stage Renal Disease Patients: Methodological Considerations. Canadian Journal of Kidney Health and Disease, 2016, 3, 109.	0.6	5
695	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 141-153.	1.1	42

#	Article	IF	CITATIONS
696	Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney International, 2016, 89, 666-674.	2.6	36
697	Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo. Drug Research, 2016, 66, 262-269.	0.7	10
698	Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporosis International, 2016, 27, 489-497.	1.3	33
699	Aortic Aging in ESRD: Structural, Hemodynamic, and Mortality Implications. Journal of the American Society of Nephrology: JASN, 2016, 27, 1837-1846.	3.0	63
700	Impact of non-invasive cardiovascular screening programs as a predictor of cardiovascular events among asymptomatic chronic kidney disease patients. Clinical and Experimental Nephrology, 2016, 20, 416-424.	0.7	4
701	The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. Journal of Human Hypertension, 2016, 30, 204-209.	1.0	13
702	Serum Bicarbonate Is Associated with Heart Failure in the Multi-Ethnic Study of Atherosclerosis. American Journal of Nephrology, 2017, 45, 118-126.	1.4	16
703	25-Hydroxyvitamin D-1-α-hydroxylase in apoliporotein E knockout mice: The role of protecting vascular smooth muscle cell from calcification. Biomedicine and Pharmacotherapy, 2017, 88, 971-977.	2.5	5
704	Long-term Clinical Outcome of Aortic Arch Calcification in Kidney Transplant Recipients. Transplantation Proceedings, 2017, 49, 1027-1032.	0.3	2
705	Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 79-95.	2.6	47
706	Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatric Nephrology, 2017, 32, 1221-1232.	0.9	14
707	Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation. Heart and Vessels, 2017, 32, 1109-1116.	0.5	26
708	Prevalence of abdominal artery calcification in dialysis patients with end-stage renal disease: a systematic review and meta-analysis. International Urology and Nephrology, 2017, 49, 2061-2069.	0.6	16
709	Correlation of lanthanum dosage with lanthanum deposition in the gastroduodenal mucosa of dialysis patients. Pathology International, 2017, 67, 447-452.	0.6	19
710	Impact of vascular calcification on cardiovascular mortality in hemodialysis patients: clinical significance, mechanisms and possible strategies for treatment. Renal Replacement Therapy, 2017, 3, .	0.3	19
711	Magnesium Counteracts Vascular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1431-1445.	1.1	81
712	Arterial calcification: A new perspective?. International Journal of Cardiology, 2017, 228, 11-22.	0.8	41
713	Coronary artery calcification in Korean patients with incident dialysis. Hemodialysis International,	0.4	3

#	Article	IF	CITATIONS
714	Plain pelvic/aorta radiographs as a simple guideline to predict vascular macro alcifications; one step earlier or a late sign to best weight the enemy of coronary calcification and mortality?. Hemodialysis International, 2017, 21, 142-144.	0.4	0
715	Severe aortic arch calcification predicts mortality in patients undergoing peritoneal dialysis. Journal of the Formosan Medical Association, 2017, 116, 366-372.	0.8	11
716	PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure. PLoS ONE, 2017, 12, e0180430.	1.1	10
717	The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. PLoS ONE, 2017, 12, e0174811.	1.1	29
718	Evaluation of serum homocysteine level and its relation with carotid intima-media thickness in patients of chronic kidney disease. Studia Medyczne, 2017, 33, 247-253.	0.0	1
719	Arterial stiffness: hemodialysis versus hemodiafiltration. Medicine and Pharmacy Reports, 2017, 90, 166-170.	0.2	1
720	Inhibition of endo-lysosomal function exacerbates vascular calcification. Scientific Reports, 2018, 8, 3377.	1.6	14
721	Impact of trajectories of abdominal aortic calcification over 2 years on subsequent mortality: a 10-year longitudinal study. Nephrology Dialysis Transplantation, 2018, 33, 676-683.	0.4	11
722	A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clinical Therapeutics, 2018, 40, 123-134.	1.1	7
723	Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients. Kidney International Reports, 2018, 3, 185-192.	0.4	7
724	Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis. Calcified Tissue International, 2018, 102, 310-320.	1.5	22
726	Factors Affecting Hyperphosphatemia in Hemodialysis Patients. Korean Journal of Adult Nursing, 2018, 30, 599.	0.2	2
727	Prognostic value of pre-dialysis blood pressure and risk threshold on clinical outcomes in hemodialysis patients. Medicine (United States), 2018, 97, e13485.	0.4	8
728	Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. Frontiers in Physiology, 2018, 9, 1643.	1.3	3
729	Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study. Diabetology and Metabolic Syndrome, 2018, 10, 75.	1.2	5
730	Prognostic Cardiovascular Markers in Chronic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 1388-1407.	0.9	43
731	Skeletal Variation (SV). , 2018, , 737-769.		0
732	Vitamin D in Vascular Calcification: A Double-Edged Sword?. Nutrients, 2018, 10, 652.	1.7	64

		CITATION REPORT		
#	Article		IF	Citations
733	Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. Toxins, 20	018, 10, 229.	1.5	24
734	Associations Between Kidney Disease Measures and Regional Pulse Wave Velocity in a Community-Based Cohort: The Atherosclerosis Risk in Communities (ARIC) Study. Ame Kidney Diseases, 2018, 72, 682-690.	Large prican Journal of	2.1	51
735	Cardiovascular Disease Risk in Children With Kidney Disease. Seminars in Nephrology,	2018, 38, 298-313.	0.6	25
736	Patient survival on haemodiafiltration and haemodialysis: a cohort study using the Aus Zealand Dialysis and Transplant Registry. Nephrology Dialysis Transplantation, 2019, 3	tralia and New 4, 326-338.	0.4	26
737	Aortic Calcification Affects Noninvasive Estimates of Central Blood Pressure in Patient Chronic Kidney Disease. Kidney and Blood Pressure Research, 2019, 44, 704-714.	s with Severe	0.9	5
738	Types and pathology of vascular calcification. , 2019, , 1-25.			0
739	HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth phenotype. Nature Genetics, 2019, 51, 1580-1587.	muscle cell	9.4	92
740	TCT-410 Assessing Suitability for Short-Term DAPT: Thromboresistance, Albumin Reter Endothelial Function in the Resolute Onyx Zotarolimus Versus BioFreedom Biolimus-El Coronary Stent Systems. Journal of the American College of Cardiology, 2019, 74, B40	tion, and uting 16.	1.2	0
741	Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidne Current Osteoporosis Reports, 2019, 17, 333-342.	y Disease.	1.5	14
742	Vitamin K, Vascular Calcification, and Chronic Kidney Disease: Current Evidence and U Questions. Current Developments in Nutrition, 2019, 3, nzz077.	hanswered	0.1	21
743	Supplementary nutrients for prevention of vascular calcification in patients with chron disease. Korean Journal of Internal Medicine, 2019, 34, 459-469.	ic kidney	0.7	13
745	Effect of bixalomer on coronary artery calcification in hemodialysis patients with hyperphosphatemia: a multi-center, randomized controlled trial. Renal Replacement Th	erapy, 2019, 5, .	0.3	0
746	Is the child at risk? Cardiovascular remodelling in children born to diabetic mothers. Ca the Young, 2019, 29, 467-474.	rdiology in	0.4	8
747	Risk Estimation of Aortic Stiffness in Patients with End Stage Renal Disease under Main Haemodialysis. University Heart Journal, 2019, 14, 67-70.	ntenance	0.0	0
748	The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcificatio Processes. International Journal of Molecular Sciences, 2019, 20, 5694.	n-Related	1.8	166
749	Bone-Vascular Axis in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 20	19, 26, 472-483.	0.6	53
750	Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: Re KNOW-CKD Study. Scientific Reports, 2019, 9, 16139.	sults from the	1.6	18
751	A comparison between the combined effect of calcium carbonate with sucroferric oxyl other phosphate binders: an in vitro and in vivo experimental study. BMC Nephrology,	nydroxide and 2019, 20, 465.	0.8	5

#	Article	IF	CITATIONS
752	<i>In Vivo</i> Detection of Chronic Kidney Disease Using Tissue Deformation Fields From Dynamic MR Imaging. IEEE Transactions on Biomedical Engineering, 2019, 66, 1779-1790.	2.5	17
753	Calcium phosphate product level as a predictor for arteriovenous fistula re-operations in patients with chronic renal failure. Vascular, 2019, 27, 284-290.	0.4	3
754	Cardiovascular Disease in Chronic Kidney Disease. , 2019, , 176-193.e9.		0
755	Coronary Artery Calcium Imaging for Risk Stratification. Contemporary Cardiology, 2019, , 469-480.	0.0	0
756	Microcalcification in the arterial wall and its relationship to the ultrasound criteria of maturation of the arteriovenous fistula. Journal of Vascular Access, 2019, 20, 46-51.	0.5	3
757	Investigational Pharmacological Treatments for Vascular Calcification. Advanced Therapeutics, 2019, 2, 1800094.	1.6	28
758	Sevelamer hydrochloride suppresses proliferation of parathyroid cells during the early phase of chronic renal failure in rats. Nephrology, 2019, 24, 127-133.	0.7	2
759	Association between Plasma Dehydroepiandrosterone Sulfate and Carotid Intima-Media Thickness among Male and Female Patients with End-Stage Renal Disease on Hemodialysis. CardioRenal Medicine, 2020, 10, 61-68.	0.7	1
760	Abdominal aorta calcification predicts cardiovascular but not non-cardiovascular outcome in patients receiving peritoneal dialysis. Medicine (United States), 2020, 99, e21730.	0.4	2
761	Effects of Eicosapentaenoic Acid on Arterial Calcification. International Journal of Molecular Sciences, 2020, 21, 5455.	1.8	8
762	Significance of acPWV for Survival of Hemodialysis Patients. Medicina (Lithuania), 2020, 56, 435.	0.8	4
764	Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. Bone, 2020, 138, 115460.	1.4	14
765	Elevated serum cartilage oligomeric matrix protein and the metalloproteinaseâ€ADAMTS7 levels are associated with vascular calcification in maintenance hemodialysis patients. Seminars in Dialysis, 2020, 33, 322-329.	0.7	1
766	Effect of kidney donation on bone mineral metabolism. PLoS ONE, 2020, 15, e0235082.	1.1	3
767	Impacts of Coronary Artery Calcification on Intradialytic Blood Pressure Patterns in Patients Receiving Maintenance Hemodialysis. Chonnam Medical Journal, 2020, 56, 27.	0.5	2
768	Targeting Vascular Calcification in Chronic Kidney Disease. JACC Basic To Translational Science, 2020, 5, 398-412.	1.9	95
769	The Role of Gut Dysbiosis in the Bone–Vascular Axis in Chronic Kidney Disease. Toxins, 2020, 12, 285.	1.5	23
770	The protective effects of renin–angiotensin system componts on vascular calcification. Journal of Human Hypertension, 2021, 35, 410-418.	1.0	5

	CITATION R	EPORT	
#	Article	IF	Citations
771	Vascular calcification by conventional X-ray and mortality in a cohort of predominantly African descent hemodialysis patients. International Journal of Artificial Organs, 2021, 44, 318-324.	0.7	2
772	Diagnostic value of fibroblast growth factor 23 for abdominal aortic calcification in Indonesian hemodialysis patients. Tzu Chi Medical Journal, 2021, 33, 154.	0.4	1
773	Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2021, 32, 723-735.	3.0	41
774	Cardiovascular risk assessment and coronary artery calcification burden in asymptomatic patients in the initial years of hemodialysis. Therapeutic Apheresis and Dialysis, 2022, 26, 64-70.	0.4	3
775	Cardiovascular Disease in Chronic Kidney Disease. Circulation, 2021, 143, 1157-1172.	1.6	680
776	Clinical Associations between Serial Electrocardiography Measurements and Sudden Cardiac Death in Patients with End-Stage Renal Disease Undergoing Hemodialysis. Journal of Clinical Medicine, 2021, 10, 1933.	1.0	1
777	Effects of on-line hemodiafiltration regimens and dialysate composition on serum concentrations of magnesium and calcium ions. Renal Replacement Therapy, 2021, 7, .	0.3	0
778	Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrology Dialysis Transplantation, 2022, 37, 663-672.	0.4	33
779	Cardiovascular magnetic resonance for the detection of descending thoracic aorta calcification in patients with end-stage renal disease. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 85.	1.6	3
780	The effect of arterial stiffness on cuff-based blood pressure measurement. Extreme Mechanics Letters, 2021, 48, 101298.	2.0	5
781	Prevalence, progression and implications of breast artery calcification in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 295-302.	1.4	6
782	Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD. American Journal of Nephrology, 2021, 52, 304-317.	1.4	1
783	Vascular Calcification in Chronic Kidney Disease. , 2009, , 697-711.		2
784	Cardiac disease in chronic uremia. , 2004, , 765-790.		3
785	Vitamin D: Normal Physiology and Vitamin D Therapeutics in Normal Nutrition and Various Disease States. , 2002, , 263-305.		1
786	Pathophysiology and Treatment of Secondary and Tertiary Hyperparathyroidism. , 2007, , 293-310.		2
787	Kidney Disease. , 2012, , 1523-1607.		5
788	Evaluation of aortic stiffness in tobacco-smoking adolescents. Journal of Adolescent Health, 2004, 34, 339-343.	1.2	10

#	Article	IF	CITATIONS
789	Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. Nature Communications, 2020, 11, 721.	5.8	38
792	Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. Journal of Clinical Investigation, 2010, 120, 203-213.	3.9	181
793	The relationship between intradialytic hypotension and vascular calcification in hemodialysis patients. PLoS ONE, 2017, 12, e0185846.	1.1	21
794	Coronary calcification in patients with end-stage renal disease: a novel endocrine disorder?. Hormones, 2007, 6, 120-131.	0.9	8
795	Effects of Sevelamer Hydrochloride on Uremic Toxins Serum Indoxyl Sulfate and P-Cresyl Sulfate in Hemodialysis Patients. Journal of Clinical Medicine Research, 2017, 9, 765-770.	0.6	17
796	Role of Calcium-Phosphate Product and Bone-Associated Proteins on Vascular Calcification in Renal Failure. Journal of the American Society of Nephrology: JASN, 2001, 12, 2511-2516.	3.0	160
797	Lower-Extremity Peripheral Arterial Disease among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2001, 12, 2838-2847.	3.0	231
798	Adynamic Renal Osteodystrophy. Journal of the American Society of Nephrology: JASN, 2001, 12, 1978-1985.	3.0	68
799	Contribution of Volume Overload and Angiotensin II to the Increased Pulse Wave Velocity of Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 177-183.	3.0	90
800	The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism. Journal of the American Society of Nephrology: JASN, 2002, 13, 1017-1024.	3.0	234
801	Peritoneal Dialysis in the 21st Century. Journal of the American Society of Nephrology: JASN, 2002, 13, S104-S115.	3.0	74
802	The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging, 2019, 11, 4274-4299.	1.4	64
803	Utilization of titanium oxide-like compound as an inorganic phosphate adsorbent for the control of serum phosphate level in chronic renal failure. Journal of Medical Investigation, 2010, 57, 275-283.	0.2	1
804	Arterial calcification: cardiovascular function and clinical outcome. Nefrologia, 2011, 31, 644-7.	0.2	29
805	Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients. Korean Journal of Internal Medicine, 2013, 28, 668.	0.7	14
806	The effects of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients with citrate dialysate. Nihon Toseki Igakkai Zasshi, 2010, 43, 373-379.	0.2	2
807	Clinical Practice Guideline for CKD-MBD. Nihon Toseki Igakkai Zasshi, 2012, 45, 301-356.	0.2	20
808	The effect of serum fetuin-A on atherosclerosis in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, 26, 370.	0.4	1

		PORT	
# 809	ARTICLE Dietary phosphate: what do we know about its toxicity. Journal of Nephrology, 2013, 26, 856-864.	IF 0.9	Citations
810	Vascular calcification: When should we interfere in chronic kidney disease patients and how?. World Journal of Nephrology, 2016, 5, 398.	0.8	18
811	Role of different imaging modalities of vascular calcification in predicting outcomes in chronic kidney disease. World Journal of Nephrology, 2017, 6, 100.	0.8	29
812	Risk factors for carotid artery distensibility in middle-aged and elderly hemodialysis patients. World Journal of Emergency Medicine, 2011, 2, 137.	0.5	2
814	Effectiveness and safety of a 6-month treatment with paricalcitol in patients on hemodialysis with secondary hyperparathyroidism. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2016, 38, 302-312.	0.4	5
815	Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. Drugs in Context, 2017, 6, 1-12.	1.0	2
816	Pulp Stone, Haemodialysis, End-stage Renal Disease, Carotid Atherosclerosis. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 1228-31.	0.8	5
817	Co-relation Between Calcium-Phosphorus Product and Hypertension in End-Stage Renal Disease Patients. Cureus, 2021, 13, e18885.	0.2	1
818	Renal Bone Diseases. , 2001, , 635-661.		1
819	Blood pressure control in chronic hemodialysis patients. , 2004, , 741-764.		0
821	Treatment of renal bone disease. , 2004, , 279-294.		1
822	å¡©é,ã,»ãf™ãf©ãfžãf¼ã®è‡"床 第49å›žæ—¥æœ¬é€æžåŒ»å¦ä¼šã,∙ãf³ãfē,,ã,¦ãfã,^ã,Š. Nihon Toseki Ig	ak ka izZass	shi, 2004, 3 7,
823	Cardiovascular considerations of pediatric ESRD. , 2004, , 353-367.		5
824	The uremic syndrome and pathophysiology of chronic renal failure. , 2004, , 57-72.		Ο
825	The factors affecting aortic and valvular calcification in hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2005, 38, 1195-1200.	0.2	0
826	Relationship between arterial stiffness and cardiovascular structural change in hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2005, 38, 1305-1314.	0.2	0
827	Dramatic reduction of the tumoral calcification treated with sevelamer hydrochloride and surgical removal of autotransplanted parathyroid tissue. Nihon Toseki Igakkai Zasshi, 2006, 39, 1191-1195.	0.2	0
828	Renal Nutrition. , 2006, , .		0

ARTICLE

829

Management of Secondary and Tertiary Hyperparathyroidism. , 2009, , 307-320. EvoluciÃ³n del compromiso cardiovascular de pacientes insuficientes renales, en hemodiálisis, sin bloqueo del eje renina-angiotensina. Revista Medica De Chile, 2009, 137, . 832 0.1 1 Disturbed Calcium-Phosphorus Metabolism/Arterial Calcifications: Consequences on Cardiovascular

逿žæ,£è€...ã®å¾ªç'°å™"å•伵症Up to Date ―第51回日本逿žåŒ»å¦ä¼šæ•™è,²è¬›æ¼"ã,^ã,Šâ€•.Ѡhon Toœki Igakkai

Natural History and Impact of Interventions on Coronary Calcium., 2010, , 59-68. 834

Function and Clinical Outcome., 2010, , 269-277.

834	Natural History and Impact of Interventions on Coronary Calcium. , 2010, , 59-68.		0
835	Impaired Autonomic Blood Pressure and Blood Volume Control in Chronic Renal Failure. , 2010, , 291-297.		0
836	Screening for Coronary Artery Calcium. , 2011, , 521-534.		0
839	Serum levels of advanced glycation end-products (AGEs) in dialysis patients. Nihon Toseki Igakkai Zasshi, 2013, 46, 467-473.	0.2	1
840	The Role of 3 - Dimensional Multi - Detector Computed Tomography in the Diagnosis of Eagle's Syndrome and Correlation with Severe Headache and Migraine : Iraqi Study. Journal of Baghdad College of Dentistry, 2013, 25, 72-76.	0.1	0
841	Bone and Mineral Disorders. , 2014, , 247-269.		0
842	Vascular Calcification. , 2014, , 1-18.		0
843	Arterial Changes in Renal Transplantation. , 2014, , 351-361.		0
844	Chronic Kidney Disease and Cardiovascular Risk. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 49-61.	0.4	0
845	Renal Bone Diseases. , 1999, , 119-127.		0
846	Vascular Access Calcification and Arteriovenous Fistula Maturation. The Open Urology & Nephrology Journal, 2014, 7, 22-25.	0.2	1
849	Vascular Calcification. , 2015, , 327-341.		0
850	Natural History and Impact of Interventions on CAC. , 2016, , 121-132.		0

851	Assessment of Arterial Stiffening and Vascular Calcifications in Endâ€Stage Renal Disease Patients. World Journal of Cardiovascular Diseases, 2017, 07, 131-143.	0.0	0
-----	---	-----	---

	CITATION	CITATION REPORT	
#	ARTICLE	IF	CITATIONS
852	The Relationship between subclinical hypothyroidism with Parathyroid hormone levels and Lipid profiles in patients on dialysis. Iranian Journal of Psychiatric Nursing, 2018, 12, 45-50.	0.1	0
853	The evaluation of the relationship between fetuin-A and traditional and non-traditional cardiovascular risk factors in kidney transplantation recipients. The European Research Journal, O, , .	0.1	0
854	Calcium, phosphate, PTH, vitamin D, and FGF-23 in CKD-mineral and bone disorder. , 2022, , 353-381.		2
855	Bone and Mineral Disorders. , 2020, , 431-456.		0
857	Natural History and Impact of Interventions on Coronary Calcium. , 2006, , 97-106.		0
858	Historical Perspective of Calcium Management in Patients with Chronic Renal Diseases. , 2006, , 1-11.		0
859	Bone and Mineral Metabolism and Disease. , 2008, , 357-385.		0
860	Sevelamer hydrochloride: a calcium- and metal-free phosphate binder. Therapy: Open Access in Clinical Medicine, 2005, 2, 823-834.	0.2	0
861	Styloid Process Elongation or Eagle's Syndrome: Is There Any Role for Ectopic Calcification?. European Journal of Dentistry, 2008, 2, 224-8.	0.8	9
862	Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia, 2011, 15, 22-6.	0.3	15
863	Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value. Core Evidence, 2005, 1, 43-63.	4.7	2
865	The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clinical Nephrology, 2010, 74, 423-32.	0.4	35
866	Klotho protein lowered in elderly hypertension. International Journal of Clinical and Experimental Medicine, 2014, 7, 2347-50.	1.3	13
867	Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication. Korean Circulation Journal, 2021, 51, 961.	0.7	17
868	$ heta_i$ ardiorenal Syndrome in Patients on Renal Replacement Therapy. , 0, , .		0
869	Association between bone mineral metabolism and vascular calcification in end-stage renal disease. BMC Nephrology, 2022, 23, 12.	0.8	7
870	High prevalence of middle cerebral artery calcification is associated with cardiovascular mortality in hemodialyzed patients: an overlooked part of arterial tree?. International Urology and Nephrology, 2022, , 1.	0.6	0
871	Past, Present, and Future of Phosphate Management. Kidney International Reports, 2022, 7, 688-698.	0.4	20

#	Article	IF	Citations
872	Vitamin D Analogues and Fracture Risk in Chronic Kidney Disease: A Systematic Review and <scp>Metaâ€Analysis</scp> of Randomized Controlled Trials. JBMR Plus, 2022, 6, e10611.	1.3	6
873	The Relationship of Epicardial Adipose Tissue and Cardiovascular Disease in Chronic Kidney Disease and Hemodialysis Patients. Journal of Clinical Medicine, 2022, 11, 1308.	1.0	5
874	Arterial stiffness and pulsatile hemodynamics in coronary artery disease and other forms of atherosclerotic vascular diseases. , 2022, , 621-635.		0
875	The Association of Dental Pulp Stones to Cardiovascular and Renal Diseases: A Systematic Review and Meta-Analysis. Journal of Endodontics, 2022, 48, 845-854.	1.4	2
876	Regression of vascular calcification in a patient treated with cinacalcet: a case report. Nefrologia, 2011, 31, 602-6.	0.2	5
877	The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation. Frontiers in Medicine, 2022, 9, .	1.2	6
878	Reduction in Arterial Stiffness after Switching from Pravastatin or Atorvastatin to Fluvastatin. Vascular Failure, 2021, 5, 23-30.	0.2	0
880	Boosted machine learning model for predicting intradialytic hypotension using serum biomarkers of nutrition. Computers in Biology and Medicine, 2022, 147, 105752.	3.9	7
881	Combined Cardiomegaly and Aortic Arch Calcification Predict Mortality in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 0, , .	0.4	0
885	Towards a better understanding of arterial calcification disease progression in CKD: investigation of early pathological alterations. Nephrology Dialysis Transplantation, 2023, 38, 1127-1138.	0.4	1
886	Alpha <scp>2â€Heremans‣chmid</scp> glycoprotein gene polymorphism (rs4918) is associated with coronary artery calcification in incident peritoneal dialysis patients. Nephrology, 2023, 28, 28-35.	0.7	0
889	Imbalance in Bone Morphogenic Proteins 2 and 7 Is Associated with Renal and Cardiovascular Damage in Chronic Kidney Disease. International Journal of Molecular Sciences, 2023, 24, 40.	1.8	4
890	Circumferential Strain as a Marker of Vessel Reactivity in Patients with Intradialytic Hypotension. Medicina (Lithuania), 2023, 59, 102.	0.8	0
891	Fibroblast growth factor 23 is independently associated with renal magnesium handling in patients with chronic kidney disease. Frontiers in Endocrinology, 0, 13, .	1.5	1
892	Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications. CKJ: Clinical Kidney Journal, 2023, 16, 928-938.	1.4	5
893	The Evolving World of Chronic Kidney Disease Mineral Bone Disorder. , 0, , 20-31.		3
894	Left sided valvular heart disease in dialysis recipients: a single centre observational study. CKJ: Clinical Kidney Journal, 0, , .	1.4	1
895	The pathophysiology and management of vascular calcification in chronic kidney disease patients. Expert Review of Cardiovascular Therapy, 2023, 21, 75-85.	0.6	6

		CITATION REPORT	
#	Article	IF	CITATIONS
896	Atherosclerosis And Inflammatory Status In Chronic Kidney Disease Patients After Renal Transplantation: Where Are We Now?. European Medical Journal Urology, 0, , 74-82.	0.0	0
898	Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease. Circulation Research, 2023, 132, 970-992.	2.0	13